Also trades as: 0IFK.L (LSE) · $vol 0M
EDIT NASDAQ
Editas Medicine, Inc.
1W: -0.8%
1M: -7.0%
3M: -8.4%
YTD: +17.1%
1Y: -34.2%
3Y: -62.7%
5Y: -93.7%
$2.60
+0.20 (+8.33%)
After Hours: $2.54 (-0.06, -2.50%)
Weekly Expected Move ±10.8%
$2
$2
$2
$3
$3
Credit Risk of going bust: higher than 56% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.3%), Editas Medicine, Inc. would be worth roughly what it owes.
Total debt $15.5M against a stock market value of $368.6M.
Distance to default 4.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.8M (short-term plus half of long-term), stock volatility 81.2%; Altman Z'' -20.04. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.3%), Editas Medicine, Inc. would be worth roughly what it owes.
Total debt $15.5M against a stock market value of $368.6M.
Distance to default 4.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.8M (short-term plus half of long-term), stock volatility 81.2%; Altman Z'' -20.04. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#338
of 1061
Biotechnology
Technical Signal Map
72 Bullish
17 Neutral
280 Bearish
EDIT
$370M
Editas Medicine, Inc.
BEARISH
-50
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
VCEL
$2.2B
Vericel Corporation
BULLISH
+100
LKFT
$2.1B
Lakefront Biotherapeutics N.V.
BULLISH
+100
SGP
$950M
SpyGlass Pharma, Inc. Common Stock
BULLISH
+100
VSTM
$910M
Verastem, Inc.
BULLISH
+100
SOLTF
$770M
Nxera Pharma Co., Ltd.
BULLISH
+100
ARQT
$3.9B
Arcutis Biotherapeutics, Inc.
BULLISH
+91
BVNRY
$2.9B
Bavarian Nordic A/S
BULLISH
+91
FTRE
$2.2B
Fortrea Holdings Inc.
BULLISH
+91
AGIO
$2.2B
Agios Pharmaceuticals, Inc.
BULLISH
+91
ENTX
$510M
Entera Bio Ltd.
BULLISH
+91
XFOR
$320M
X4 Pharmaceuticals, Inc.
BULLISH
+87
LEGN
$3.6B
Legend Biotech Corporation
BULLISH
+84
KRRO
$180M
Korro Bio, Inc.
BULLISH
+84
HURA
$140M
TuHURA Biosciences, Inc.
BULLISH
+84
VRDN
$2.5B
Viridian Therapeutics, Inc.
BULLISH
+78
AUPH
$2.2B
Aurinia Pharmaceuticals Inc.
BULLISH
+75
BHVN
$2.1B
Biohaven Ltd.
BULLISH
+75
RIGL
$900M
Rigel Pharmaceuticals, Inc.
BULLISH
+75
IRON
$2.9B
Disc Medicine, Inc.
BULLISH
+66
NRIX
$2.8B
Nurix Therapeutics, Inc.
BULLISH
+66
ZYME
$2.0B
Zymeworks Inc.
BULLISH
+66
XNCR
$1.9B
Xencor, Inc.
BULLISH
+66
KLRA
$1.7B
Kailera Therapeutics, Inc.
BULLISH
+66
TRAX
$1.6B
First Tracks Biotherapeutics Inc
BULLISH
+66
LBRX
$1.2B
LB Pharmaceuticals Inc Common Stock
BULLISH
+66
SLN
$930M
Silence Therapeutics plc
BULLISH
+66
PBYI
$570M
Puma Biotechnology, Inc.
BULLISH
+66
MXCT
$140M
MaxCyte, Inc.
BULLISH
+66
ORKA
$5.3B
Oruka Therapeutics, Inc.
BULLISH
+62
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+59
ERAS
$5.0B
Erasca, Inc.
BULLISH
+59
PHAR
$710M
Pharming Group N.V.
BULLISH
+59
INDP
$360M
Indaptus Therapeutics, Inc.
BULLISH
+59
OABIW
$1.1B
OmniAb, Inc.
BULLISH
+58
DMAC
$470M
DiaMedica Therapeutics Inc.
BULLISH
+58
SCNLF
$170M
Scancell Holdings plc
BULLISH
+58
ONTTF
$2.7B
Oxford Nanopore Technologies plc
BULLISH
+56
SPTX
$1.1B
Seaport Therapeutics, Inc. Common Stock
BULLISH
+55
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
ADMA
$2.4B
ADMA Biologics, Inc.
BULLISH
+53
CASBF
$1.4B
CanSino Biologics Inc.
BULLISH
+52
BRVE
$1.5B
Braveheart Bio, Inc.
BULLISH
+51
SEPN
$1.9B
Septerna Inc
BULLISH
+50
MAZE
$1.7B
Maze Therapeutics, Inc.
BULLISH
+50
COAG
$1.6B
Hemab Therapeutics Holdings, Inc. Common Stock
BULLISH
+50
CRMD
$610M
CorMedix Inc.
BULLISH
+50
ADCT
$180M
ADC Therapeutics S.A.
BULLISH
+49
PRME
$670M
Prime Medicine, Inc.
BULLISH
+44
NAUT
$410M
Nautilus Biotechnolgy, Inc.
BULLISH
+44
RARE
$1.5B
Ultragenyx Pharmaceutical Inc.
BULLISH
+43
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+42
IMCR
$1.6B
Immunocore Holdings plc
BULLISH
+41
XERS
$1.9B
Xeris Biopharma Holdings, Inc.
BULLISH
+40
NBTX
$1.5B
Nanobiotix S.A.
BULLISH
+35
DMRA
$1.3B
Damora Therapeutics, Inc.
BULLISH
+34
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+33
VIR
$1.8B
Vir Biotechnology, Inc.
BULLISH
+33
SLGL
$230M
Sol-Gel Technologies Ltd.
BULLISH
+33
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
BULLISH
+31
CYDY
$380M
CytoDyn Inc.
BULLISH
+31
ABOS
$140M
Acumen Pharmaceuticals, Inc.
LEAN BULL
+27
TGTX
$8.3B
TG Therapeutics, Inc.
LEAN BULL
+26
MRVI
$2.1B
Maravai LifeSciences Holdings, Inc.
LEAN BULL
+26
PTCHF
$390M
PureTech Health plc
LEAN BULL
+26
SGMT
$310M
Sagimet Biosciences Inc.
LEAN BULL
+25
MLTX
$1.0B
MoonLake Immunotherapeutics
LEAN BULL
+23
KOD
$5.5B
Kodiak Sciences Inc.
LEAN BULL
+18
HSTC
$210M
HST Global, Inc.
LEAN BULL
+13
RXRX
$2.0B
Recursion Pharmaceuticals, Inc.
LEAN BULL
+12
LCTX
$250M
Lineage Cell Therapeutics, Inc.
LEAN BULL
+11
ZLAB
$2.7B
Zai Lab Limited
NEUTRAL
+8
LYEL
$230M
Lyell Immunopharma, Inc.
NEUTRAL
+7
PRLD
$210M
Prelude Therapeutics Incorporated
NEUTRAL
+7
PTGX
$9.0B
Protagonist Therapeutics, Inc.
NEUTRAL
+2
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
NWBO
$260M
Northwest Biotherapeutics, Inc.
NEUTRAL
+2
MLLCF
$150M
Molecular Partners AG
NEUTRAL
+2
REPL
$1.1B
Replimune Group, Inc.
NEUTRAL
+1
LYCA
$1.6B
Lycia Therapeutics Inc.
N/A
0
CTY
$200M
City Therapeutics Inc.
N/A
0
IAM
$130M
Iambic Therapeutics Inc.
N/A
0
PHMMF
$1.6B
Pharma Mar, S.A.
NEUTRAL
-3
SRZN
$190M
Surrozen, Inc.
NEUTRAL
-3
YARW
$180M
Yarrow Bioscience Inc
NEUTRAL
-6
VCRE
$260M
Vicore Pharma Holding AB
NEUTRAL
-8
KROS
$220M
Keros Therapeutics, Inc.
NEUTRAL
-8
ANAB
$1.5B
AnaptysBio, Inc.
NEUTRAL
-9
ODTX
$940M
Odyssey Therapeutics, Inc.
LEAN BEAR
-11
GLPGF
$2.1B
Lakefront Biotherapeutics
LEAN BEAR
-12
INRLF
$640M
Valneva SE
LEAN BEAR
-12
COGT
$5.4B
Cogent Biosciences, Inc.
LEAN BEAR
-15
DFTX
$4.8B
Definium Therapeutics, Inc.
LEAN BEAR
-15
INVA
$1.5B
Innoviva, Inc.
LEAN BEAR
-15
RLAY
$4.0B
Relay Therapeutics, Inc.
LEAN BEAR
-16
NURPF
$1.8B
Neuren Pharmaceuticals Limited
LEAN BEAR
-17
DTIL
$180M
Precision BioSciences, Inc.
LEAN BEAR
-17
PEPG
$170M
PepGen Inc.
LEAN BEAR
-17
JBIO
$930M
Jade Biosciences, Inc.
LEAN BEAR
-18
ACRS
$550M
Aclaris Therapeutics, Inc.
LEAN BEAR
-18
ALMR
$2.1B
Alamar Biosciences, Inc.
LEAN BEAR
-19
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
SHJBF
$4.8B
Shanghai Junshi Biosciences Co., Ltd.
LEAN BEAR
-20
KRSA
$150M
Korsana Biosciences, Inc.
LEAN BEAR
-20
TYRA
$1.2B
Tyra Biosciences, Inc.
LEAN BEAR
-22
CLDX
$2.3B
Celldex Therapeutics, Inc.
LEAN BEAR
-24
ZBIO
$1.8B
Zenas BioPharma, Inc.
LEAN BEAR
-24
ENTA
$340M
Enanta Pharmaceuticals, Inc.
LEAN BEAR
-24
APLMW
$170M
Apollomics, Inc.
LEAN BEAR
-24
ARMP
$140M
Armata Pharmaceuticals, Inc.
LEAN BEAR
-24
GWIN
$360M
Glorywin Entertainment Group, Inc.
LEAN BEAR
-25
FGHQF
$360M
Frontage Holdings Corporation
LEAN BEAR
-25
SPHRY
$220M
Starpharma Holdings Limited
LEAN BEAR
-25
ALEC
$200M
Alector, Inc.
LEAN BEAR
-26
SRRK
$5.0B
Scholar Rock Holding Corporation
LEAN BEAR
-27
ELVN
$3.0B
Enliven Therapeutics, Inc.
LEAN BEAR
-27
STOK
$1.6B
Stoke Therapeutics, Inc.
LEAN BEAR
-27
AVLN
$1.1B
Avalyn Pharma Inc. Common Stock
BEARISH
-31
DBVT
$230M
DBV Technologies S.A.
BEARISH
-31
RNA
$140M
Atrium Therapeutics, Inc.
BEARISH
-31
DRUG
$520M
Bright Minds Biosciences Inc.
BEARISH
-32
TRDA
$170M
Entrada Therapeutics, Inc.
BEARISH
-32
ABSI
$1.6B
Absci Corporation
BEARISH
-33
SNBIF
$1.3B
SanBio Company Limited
BEARISH
-33
FATE
$250M
Fate Therapeutics, Inc.
BEARISH
-33
NTLA
$1.6B
Intellia Therapeutics, Inc.
BEARISH
-34
JANX
$1.0B
Janux Therapeutics, Inc.
BEARISH
-34
BPMUF
$960M
Basilea Pharmaceutica AG
BEARISH
-34
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
BEARISH
-35
ACAD
$3.4B
Acadia Pharmaceuticals Inc.
BEARISH
-35
PVLA
$1.8B
Palvella Therapeutics, Inc.
BEARISH
-35
IFRX
$230M
InflaRx N.V.
BEARISH
-35
ATGGF
$140M
Actinogen Medical Limited
BEARISH
-35
MEOBF
$2.0B
Mesoblast Limited
BEARISH
-37
EWTX
$4.2B
Edgewise Therapeutics, Inc.
BEARISH
-40
ADPT
$4.1B
Adaptive Biotechnologies Corporation
BEARISH
-40
PHVS
$2.2B
Pharvaris N.V.
BEARISH
-40
OCS
$490M
Oculis Holding AG
BEARISH
-40
ALXO
$160M
ALX Oncology Holdings Inc.
BEARISH
-40
FBIOP
$130M
Fortress Biotech, Inc.
BEARISH
-40
KARD
$1.1B
Kardigan, Inc.
BEARISH
-41
PPTDF
$870M
PeptiDream Inc.
BEARISH
-41
SLS
$2.3B
SELLAS Life Sciences Group, Inc.
BEARISH
-42
SRPT
$1.9B
Sarepta Therapeutics, Inc.
BEARISH
-42
CSPHF
$1.4B
CStone Pharmaceuticals
BEARISH
-42
DRTSW
$1.2B
Alpha Tau Medical Ltd.
BEARISH
-42
OVID
$420M
Ovid Therapeutics Inc.
BEARISH
-42
NGNE
$370M
Neurogene Inc.
BEARISH
-42
TNGX
$3.9B
Tango Therapeutics, Inc.
BEARISH
-43
IMNM
$2.1B
Immunome, Inc.
BEARISH
-44
RAPP
$1.2B
Rapport Therapeutics, Inc. Common Stock
BEARISH
-44
CGEM
$880M
Cullinan Therapeutics, Inc.
BEARISH
-44
ADRX
$1.9B
ADARx Pharmaceuticals, Inc.
BEARISH
-46
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-47
CRVS
$890M
Corvus Pharmaceuticals, Inc.
BEARISH
-48
GLSI
$240M
Greenwich LifeSciences, Inc.
BEARISH
-48
XENE
$3.4B
Xenon Pharmaceuticals Inc.
BEARISH
-49
CELC
$3.2B
Celcuity Inc.
BEARISH
-49
DYN
$2.9B
Dyne Therapeutics, Inc.
BEARISH
-49
TSHA
$1.3B
Taysha Gene Therapies, Inc.
BEARISH
-49
ARVN
$470M
Arvinas, Inc.
BEARISH
-49
PRTA
$420M
Prothena Corporation plc
BEARISH
-49
CCCC
$380M
C4 Therapeutics, Inc.
BEARISH
-49
AAPG
$1.4B
Ascentage Pharma Group International
BEARISH
-50
TTRX
$310M
Turn Therapeutics Inc.
BEARISH
-50
DNA
$670M
Ginkgo Bioworks Holdings, Inc.
BEARISH
-51
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
HNSBF
$330M
Hansa Biopharma AB (publ)
BEARISH
-53
VBIZF
$400M
Viva Biotech Holdings
BEARISH
-56
SPRB
$130M
Spruce Biosciences, Inc.
BEARISH
-56
MIRM
$5.2B
Mirum Pharmaceuticals, Inc.
BEARISH
-58
IMTX
$1.1B
Immatics N.V.
BEARISH
-58
AVBP
$1.0B
ArriVent BioPharma, Inc.
BEARISH
-58
ZURA
$320M
Zura Bio Limited
BEARISH
-58
BCYC
$250M
Bicycle Therapeutics plc
BEARISH
-58
CLVLF
$250M
Clinuvel Pharmaceuticals Limited
BEARISH
-58
CDXS
$140M
Codexis, Inc.
BEARISH
-58
TWST
$9.2B
Twist Bioscience Corporation
BEARISH
-59
ABCL
$3.8B
AbCellera Biologics Inc.
BEARISH
-59
CAMRF
$3.7B
Camurus AB
BEARISH
-59
AURA
$650M
Aura Biosciences, Inc.
BEARISH
-59
ARCT
$280M
Arcturus Therapeutics Holdings Inc.
BEARISH
-59
DNTH
$4.3B
Dianthus Therapeutics, Inc.
BEARISH
-60
IDRSF
$1.4B
Idorsia Ltd
BEARISH
-60
QTTB
$260M
Q32 Bio Inc.
BEARISH
-60
RCUS
$2.3B
Arcus Biosciences, Inc.
BEARISH
-62
AUTL
$410M
Autolus Therapeutics plc
BEARISH
-62
PRAX
$7.1B
Praxis Precision Medicines, Inc.
BEARISH
-65
BEAM
$2.5B
Beam Therapeutics Inc.
BEARISH
-66
VOR
$990M
Vor Biopharma Inc.
BEARISH
-66
ASCLF
$770M
Ascletis Pharma Inc.
BEARISH
-66
YDES
$350M
YD Bio Limited Ordinary Shares
BEARISH
-66
CAMP
$210M
CAMP4 Therapeutics Corporation
BEARISH
-66
RNAC
$190M
Cartesian Therapeutics, Inc.
BEARISH
-66
VRXA
$140M
Veraxa Biotech Holding AG
BEARISH
-66
OTLK
$130M
Outlook Therapeutics, Inc.
BEARISH
-66
OBIO
$340M
Orchestra BioMed Holdings, Inc.
BEARISH
-68
ACOG
$130M
Alpha Cognition Inc
BEARISH
-68
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-69
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-69
TRVI
$1.8B
Trevi Therapeutics, Inc.
BEARISH
-69
QURE
$1.6B
uniQure N.V.
BEARISH
-69
MGTX
$880M
MeiraGTx Holdings plc
BEARISH
-69
ABUS
$830M
Arbutus Biopharma Corp
BEARISH
-69
AMGXF
$140M
AnGes, Inc.
BEARISH
-69
NWPHF
$410M
Newron Pharmaceuticals S.p.A.
BEARISH
-71
DNLI
$2.9B
Denali Therapeutics Inc.
BEARISH
-74
MNKD
$1.0B
MannKind Corporation
BEARISH
-74
APMD
$790M
Apnimed, Inc.
BEARISH
-74
SABS
$260M
SAB Biotherapeutics, Inc.
BEARISH
-74
IMRX
$240M
Immuneering Corporation
BEARISH
-74
TXG
$9.3B
10x Genomics, Inc.
BEARISH
-75
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-75
CGON
$5.5B
CG Oncology Inc.
BEARISH
-75
AMLX
$3.4B
Amylyx Pharmaceuticals, Inc.
BEARISH
-75
INCPF
$2.4B
InnoCare Pharma Limited
BEARISH
-75
BCRX
$1.9B
BioCryst Pharmaceuticals, Inc.
BEARISH
-75
GENB
$1.6B
Generate Biomedicines, Inc.
BEARISH
-75
CMPS
$1.6B
COMPASS Pathways plc
BEARISH
-75
INBX
$1.4B
Inhibrx Biosciences Inc.
BEARISH
-75
OMER
$1.2B
Omeros Corporation
BEARISH
-75
ACHV
$670M
Achieve Life Sciences, Inc.
BEARISH
-75
NVCT
$650M
Nuvectis Pharma, Inc.
BEARISH
-75
MDXG
$570M
MiMedx Group, Inc.
BEARISH
-75
STTK
$550M
Shattuck Labs, Inc.
BEARISH
-75
CBIO
$480M
Crescent Biopharma, Inc.
BEARISH
-75
RZLT
$370M
Rezolute, Inc.
BEARISH
-75
FENC
$350M
Fennec Pharmaceuticals Inc.
BEARISH
-75
DMTRF
$310M
3-D Matrix, Ltd.
BEARISH
-75
CUE
$140M
Cue Biopharma, Inc.
BEARISH
-75
GHRS
$1.2B
GH Research PLC
BEARISH
-78
ANRO
$860M
Alto Neuroscience, Inc.
BEARISH
-78
AKTS
$850M
Aktis Oncology, Inc.
BEARISH
-78
DSGN
$640M
Design Therapeutics, Inc.
BEARISH
-78
SLDB
$630M
Solid Biosciences Inc.
BEARISH
-78
LXRX
$630M
Lexicon Pharmaceuticals, Inc.
BEARISH
-78
ANL
$560M
Adlai Nortye Ltd.
BEARISH
-78
MNPR
$470M
Monopar Therapeutics Inc.
BEARISH
-78
AVIR
$320M
Atea Pharmaceuticals, Inc.
BEARISH
-78
ARTV
$300M
Artiva Biotherapeutics, Inc.
BEARISH
-78
WHWK
$180M
Whitehawk Therapeutics Inc
BEARISH
-78
ANTX
$130M
AN2 Therapeutics, Inc.
BEARISH
-78
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
VERA
$2.0B
Vera Therapeutics, Inc.
BEARISH
-82
HBMHF
$1.3B
HBM Holdings Limited
BEARISH
-82
BCAX
$1.1B
Bicara Therapeutics Inc. Common Stock
BEARISH
-82
NKTR
$1.1B
Nektar Therapeutics
BEARISH
-82
GLUE
$920M
Monte Rosa Therapeutics, Inc.
BEARISH
-82
ALMS
$880M
Alumis Inc.
BEARISH
-82
AGMB
$450M
AgomAb Therapeutics N.V. American Depositary Shares
BEARISH
-82
BLSM
$430M
BlossomHill Therapeutics, Inc.
BEARISH
-82
EIKN
$390M
Eikon Therapeutics, Inc. Common Stock
BEARISH
-82
RLMD
$350M
Relmada Therapeutics, Inc.
BEARISH
-82
BNTC
$300M
Benitec Biopharma Inc.
BEARISH
-82
IPSC
$260M
Century Therapeutics, Inc.
BEARISH
-82
RCKT
$250M
Rocket Pharmaceuticals, Inc.
BEARISH
-82
BOVNF
$220M
BioInvent International AB (publ)
BEARISH
-82
CHRS
$160M
Coherus Oncology, Inc.
BEARISH
-82
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-84
CRSP
$4.8B
CRISPR Therapeutics AG
BEARISH
-84
IDYA
$3.4B
IDEAYA Biosciences, Inc.
BEARISH
-84
TARS
$3.2B
Tarsus Pharmaceuticals, Inc.
BEARISH
-84
TLX
$3.1B
Telix Pharmaceuticals Limited
BEARISH
-84
MBX
$2.3B
MBX Biosciences, Inc. Common Stock
BEARISH
-84
PGEN
$2.2B
Precigen, Inc.
BEARISH
-84
ORIC
$1.4B
ORIC Pharmaceuticals, Inc.
BEARISH
-84
KURA
$850M
Kura Oncology, Inc.
BEARISH
-84
FDMT
$600M
4D Molecular Therapeutics, Inc.
BEARISH
-84
ZVRA
$580M
Zevra Therapeutics, Inc.
BEARISH
-84
EPRX
$450M
Eupraxia Pharmaceuticals Inc.
BEARISH
-84
IRD
$290M
Opus Genetics, Inc.
BEARISH
-84
AGEN
$290M
Agenus Inc.
BEARISH
-84
GALT
$210M
Galectin Therapeutics Inc.
BEARISH
-84
CGEN
$180M
Compugen Ltd.
BEARISH
-84
MGNX
$140M
MacroGenics, Inc.
BEARISH
-84
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-87
TVTX
$4.7B
Travere Therapeutics, Inc.
BEARISH
-87
BRCTF
$2.6B
BioArctic AB
BEARISH
-87
HRMY
$2.1B
Harmony Biosciences Holdings, Inc.
BEARISH
-87
URGN
$1.7B
UroGen Pharma Ltd.
BEARISH
-87
NUVB
$1.6B
Nuvation Bio Inc.
BEARISH
-87
NVAX
$1.6B
Novavax, Inc.
BEARISH
-87
DRTS
$1.2B
Alpha Tau Medical Ltd
BEARISH
-87
MDCLF
$1.1B
MedinCell S.A.
BEARISH
-87
IMMX
$680M
Immix Biopharma, Inc.
BEARISH
-87
CADL
$610M
Candel Therapeutics, Inc.
BEARISH
-87
CLYM
$590M
Climb Bio, Inc.
BEARISH
-87
GNFTF
$470M
Genfit S.A.
BEARISH
-87
AVCTF
$420M
Avacta Group Plc
BEARISH
-87
IKT
$220M
Inhibikase Therapeutics, Inc.
BEARISH
-87
PLX
$210M
Protalix BioTherapeutics, Inc.
BEARISH
-87
PRQR
$180M
ProQR Therapeutics N.V.
BEARISH
-87
ORMP
$170M
Oramed Pharmaceuticals Inc.
BEARISH
-87
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
BEARISH
-91
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
PTCT
$5.1B
PTC Therapeutics, Inc.
BEARISH
-91
PBLS
$3.0B
Parabilis Medicines, Inc.
BEARISH
-91
NAMS
$2.3B
NewAmsterdam Pharma Company N.V.
BEARISH
-91
SNDX
$1.2B
Syndax Pharmaceuticals, Inc.
BEARISH
-91
ARDX
$770M
Ardelyx, Inc.
BEARISH
-91
GERN
$720M
Geron Corporation
BEARISH
-91
SANA
$700M
Sana Biotechnology, Inc.
BEARISH
-91
SLBT
$640M
SL Science Holding Ltd
BEARISH
-91
WVE
$630M
Wave Life Sciences Ltd.
BEARISH
-91
GYRE
$620M
Gyre Therapeutics, Inc.
BEARISH
-91
ANNX
$610M
Annexon, Inc.
BEARISH
-91
OLMA
$560M
Olema Pharmaceuticals, Inc.
BEARISH
-91
CTMX
$510M
CytomX Therapeutics, Inc.
BEARISH
-91
SPRY
$400M
ARS Pharmaceuticals, Inc.
BEARISH
-91
MPLT
$340M
MapLight Therapeutics, Inc.
BEARISH
-91
SPHDF
$280M
Santhera Pharmaceuticals Holding AG
BEARISH
-91
VOGX
$260M
Vogenx Inc.
BEARISH
-91
ORYZF
$250M
Oryzon Genomics S.A.
BEARISH
-91
LRMR
$240M
Larimar Therapeutics, Inc.
BEARISH
-91
HLOSF
$240M
Healios K.K.
BEARISH
-91
VNDA
$240M
Vanda Pharmaceuticals Inc.
BEARISH
-91
LXEO
$230M
Lexeo Therapeutics, Inc. Common Stock
BEARISH
-91
IPHYF
$210M
Innate Pharma S.A.
BEARISH
-91
BBOT
$210M
BridgeBio Oncology Therapeutics Inc.
BEARISH
-91
EVMN
$190M
Evommune, Inc.
BEARISH
-91
BIOA
$190M
BioAge Labs Inc.
BEARISH
-91
ELDN
$190M
Eledon Pharmaceuticals, Inc.
BEARISH
-91
AKBA
$160M
Akebia Therapeutics, Inc.
BEARISH
-91
ZNTL
$160M
Zentalis Pharmaceuticals, Inc.
BEARISH
-91
NBP
$160M
NovaBridge Biosciences
BEARISH
-91
NGEN
$150M
NervGen Pharma Corp. Common stock
BEARISH
-91
MDWD
$150M
MediWound Ltd.
BEARISH
-91
TARA
$140M
Protara Therapeutics, Inc.
BEARISH
-91
NKTX
$130M
Nkarta, Inc.
BEARISH
-91
MENS
$130M
Jyong Biotech Ltd. Ordinary Shares
BEARISH
-91
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-100
TRSBF
$4.3B
3SBio Inc.
BEARISH
-100
VKTX
$3.1B
Viking Therapeutics, Inc.
BEARISH
-100
ZLDPF
$2.4B
Zealand Pharma A/S
BEARISH
-100
GENSF
$1.8B
Genus plc
BEARISH
-100
MLYS
$1.8B
Mineralys Therapeutics, Inc.
BEARISH
-100
OCUL
$1.4B
Ocular Therapeutix, Inc.
BEARISH
-100
GPCR
$1.2B
Structure Therapeutics Inc.
BEARISH
-100
SVRA
$870M
Savara Inc.
BEARISH
-100
IVEVF
$750M
Inventiva S.A.
BEARISH
-100
ATTO
$630M
Attovia Therapeutics, Inc.
BEARISH
-100
PROK
$470M
ProKidney Corp.
BEARISH
-100
PHAT
$460M
Phathom Pharmaceuticals, Inc.
BEARISH
-100
RGNX
$440M
REGENXBIO Inc.
BEARISH
-100
FTH
$440M
Faeth Therapeutics, Inc.
BEARISH
-100
ALLO
$430M
Allogene Therapeutics, Inc.
BEARISH
-100
ALT
$410M
Altimmune, Inc.
BEARISH
-100
ASMB
$400M
Assembly Biosciences, Inc.
BEARISH
-100
TECX
$390M
Tectonic Therapeutic, Inc.
BEARISH
-100
AVTX
$370M
Avalo Therapeutics, Inc.
BEARISH
-100
CAPR
$340M
Capricor Therapeutics, Inc.
BEARISH
-100
KYTX
$330M
Kyverna Therapeutics, Inc.
BEARISH
-100
FULC
$280M
Fulcrum Therapeutics, Inc.
BEARISH
-100
CTNM
$270M
Contineum Therapeutics, Inc.
BEARISH
-100
ABEO
$250M
Abeona Therapeutics Inc.
BEARISH
-100
CABA
$250M
Cabaletta Bio, Inc.
BEARISH
-100
SCTX
$250M
Scribe Therapeutics Inc.
BEARISH
-100
OCGN
$250M
Ocugen, Inc.
BEARISH
-100
ACIU
$250M
AC Immune S.A.
BEARISH
-100
PALI
$230M
Palisade Bio, Inc.
BEARISH
-100
NAGE
$190M
Niagen Bioscience Inc
BEARISH
-100
IVVD
$180M
Invivyd, Inc.
BEARISH
-100
SION
$160M
Sionna Therapeutics, Inc.
BEARISH
-100
CNTN
$150M
Canton Strategic Holdings Inc
BEARISH
-100
UPB
$150M
Upstream Bio, Inc.
BEARISH
-100
STRO
$150M
Sutro Biopharma, Inc.
BEARISH
-100
CMPX
$140M
Compass Therapeutics, Inc.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine, Inc. | $370M | -3.4 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BEARISH | -30.1 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| VSTM Verastem, Inc. | $910M | -4.1 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 27.0 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -15.8 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| ENTX Entera Bio Ltd. | $510M | -8.8 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 37.8 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.7 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -14.5 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| KRRO Korro Bio, Inc. | $180M | -1.3 | -97.7 | -196.6 | — | -62.1 | 2 | BULLISH | -65.1 |
| HURA TuHURA Biosciences, Inc. | $140M | -3.8 | -161.4 | -137.6 | — | — | 2 | BULLISH | -7.9 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.8 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 68.7 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.4 | -25.8 | -768.9 | — | — | 2 | BULLISH | 148.2 |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 171.0 |
| PBYI Puma Biotechnology, Inc. | $570M | 20.3 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 108.8 |
| MXCT MaxCyte, Inc. | $140M | -4.7 | -20.4 | -38.9 | -122.0 | -13.2 | 2 | BULLISH | -5.5 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| PHAR Pharming Group N.V. | $710M | 81.8 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -12.7 |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -8.8 |
| OABIW OmniAb, Inc. | $1.1B | -13.8 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -17.6 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -11.9 | -114.6 | 616.3 | — | — | 2 | BULLISH | 26.3 |
| SCNLF Scancell Holdings plc | $170M | -5.1 | 153.2 | 179.2 | — | -100.0 | 2 | BULLISH | 969.8 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| CASBF CanSino Biologics Inc. | $1.4B | 367.7 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BULLISH | -25.5 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BULLISH | — |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| CRMD CorMedix Inc. | $610M | 3.3 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -28.4 |
| ADCT ADC Therapeutics S.A. | $180M | -2.4 | 45.3 | 260.9 | -86.1 | 2.0 | 2 | BULLISH | -61.1 |
| PRME Prime Medicine, Inc. | $670M | -4.0 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | -18.4 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.5 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 136.9 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| SLGL Sol-Gel Technologies Ltd. | $230M | -12.4 | -35.9 | -228.0 | 36.4 | 282.9 | 3 | BULLISH | 74.8 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| CYDY CytoDyn Inc. | $380M | -4.9 | 57.8 | 24.6 | — | 100.0 | 4 | BULLISH | -16.2 |
| ABOS Acumen Pharmaceuticals, Inc. | $140M | -1.5 | -162.7 | 466.8 | — | — | 2 | LEAN BULL | 2.3 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 69.3 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 142.2 |
| PTCHF PureTech Health plc | $390M | 157.1 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | LEAN BULL | -5.4 |
| SGMT Sagimet Biosciences Inc. | $310M | -8.2 | -24.4 | -231.4 | — | — | 3 | LEAN BULL | 14.0 |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.1 | -67.4 | 2902.7 | — | — | 1 | LEAN BULL | 25.3 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 388.6 |
| HSTC HST Global, Inc. | $210M | -538.5 | -2.5 | -1.2 | -13.7 | 564.0 | 5 | LEAN BULL | 349900.0 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | LEAN BULL | -33.0 |
| LCTX Lineage Cell Therapeutics, Inc. | $250M | -7.3 | -59.0 | -171.3 | 138.6 | 19.9 | 5 | LEAN BULL | -39.4 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| LYEL Lyell Immunopharma, Inc. | $230M | -0.6 | -93.3 | -227.7 | -1118875.0 | -55.0 | 3 | NEUTRAL | -42.6 |
| PRLD Prelude Therapeutics Incorporated | $210M | -4.9 | -57.7 | 14236.3 | -244.1 | 220.3 | 5 | NEUTRAL | 139.5 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 88.5 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| NWBO Northwest Biotherapeutics, Inc. | $260M | -6.7 | 55.8 | -188.7 | -1142.6 | 98.6 | 3 | NEUTRAL | -33.7 |
| MLLCF Molecular Partners AG | $150M | -2.3 | -62.1 | 650.3 | — | -100.0 | 2 | NEUTRAL | 14.6 |
| REPL Replimune Group, Inc. | $1.1B | -4.2 | -134.3 | -1055.2 | — | — | 1 | NEUTRAL | 48.3 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| CTY City Therapeutics Inc. | $200M | — | — | — | — | — | — | N/A | — |
| IAM Iambic Therapeutics Inc. | $130M | — | — | — | — | — | — | N/A | — |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| SRZN Surrozen, Inc. | $190M | -0.7 | 387.2 | 11.1 | 1003.5 | -8.8 | 2 | NEUTRAL | 114.8 |
| YARW Yarrow Bioscience Inc | $180M | — | — | — | — | — | — | NEUTRAL | — |
| VCRE Vicore Pharma Holding AB | $260M | — | — | — | — | — | — | NEUTRAL | — |
| KROS Keros Therapeutics, Inc. | $220M | -3.1 | -17.2 | -392.2 | — | -93.6 | 3 | NEUTRAL | -24.0 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | LEAN BEAR | — |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | LEAN BEAR | -25.4 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 111.6 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | LEAN BEAR | 18.2 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 174.6 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| DTIL Precision BioSciences, Inc. | $180M | -2.4 | -135.1 | 203.1 | — | 3473.0 | 5 | LEAN BEAR | 1.0 |
| PEPG PepGen Inc. | $170M | -1.7 | -75.5 | -327.5 | — | — | 4 | LEAN BEAR | -43.1 |
| JBIO Jade Biosciences, Inc. | $930M | -5.4 | -47.8 | 629.9 | — | — | 3 | LEAN BEAR | 47.4 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BEAR | 76.3 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| KRSA Korsana Biosciences, Inc. | $150M | — | — | — | — | — | — | LEAN BEAR | — |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.9 | -45.3 | -2390.9 | — | — | 2 | LEAN BEAR | 51.2 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | LEAN BEAR | 14.2 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -5.0 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BEAR | 15.9 |
| APLMW Apollomics, Inc. | $170M | -2.6 | -233.7 | 845.7 | 1188.0 | -75.9 | 3 | LEAN BEAR | -56.5 |
| ARMP Armata Pharmaceuticals, Inc. | $140M | -0.7 | 127.8 | -54.7 | 2953.8 | -35.1 | 2 | LEAN BEAR | -42.4 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| SPHRY Starpharma Holdings Limited | $220M | -26.0 | -46.5 | -441.4 | -725.1 | 186.8 | 4 | LEAN BEAR | 73.3 |
| ALEC Alector, Inc. | $200M | -1.9 | -385.1 | 66.8 | -692.5 | -82.9 | 1 | LEAN BEAR | 40.0 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 112.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BEAR | -19.1 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| DBVT DBV Technologies S.A. | $230M | -2.6 | -142.6 | -2201.5 | — | -100.0 | 2 | BEARISH | -34.3 |
| RNA Atrium Therapeutics, Inc. | $140M | -2.1 | -36.9 | 455.9 | -672.0 | 235.3 | 5 | BEARISH | -82.9 |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.2 | -13.7 | -105758.3 | — | — | 3 | BEARISH | -11.7 |
| TRDA Entrada Therapeutics, Inc. | $170M | -1.1 | -54.1 | -236.6 | -4762.0 | -94.1 | 1 | BEARISH | -35.4 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BEARISH | 147.5 |
| SNBIF SanBio Company Limited | $1.3B | -19.5 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| FATE Fate Therapeutics, Inc. | $250M | -2.0 | -60.7 | -140.1 | -1448.6 | -23.4 | 2 | BEARISH | 115.1 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BEARISH | -52.0 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.4 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | BEARISH | -30.7 |
| BPMUF Basilea Pharmaceutica AG | $960M | 16.9 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -16.6 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -8.4 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | BEARISH | 82.1 |
| IFRX InflaRx N.V. | $230M | -3.0 | -38.5 | 251.5 | — | -106.2 | 4 | BEARISH | 18.6 |
| ATGGF Actinogen Medical Limited | $140M | -8.5 | -77.5 | -235.8 | — | -100.0 | 1 | BEARISH | 17.2 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 160.4 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 60.6 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 39.0 |
| OCS Oculis Holding AG | $490M | -4.7 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.1 |
| ALXO ALX Oncology Holdings Inc. | $160M | -1.0 | -80.6 | -851.1 | — | — | 4 | BEARISH | -37.1 |
| FBIOP Fortress Biotech, Inc. | $130M | 0.6 | 107.5 | -87.8 | -2.5 | 15.5 | 6 | BEARISH | 131.0 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | BEARISH | — |
| PPTDF PeptiDream Inc. | $870M | -38.0 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 511.6 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BEARISH | -17.2 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 807.7 |
| OVID Ovid Therapeutics Inc. | $420M | -4.7 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | BEARISH | 38.6 |
| NGNE Neurogene Inc. | $370M | -4.9 | -45.3 | -111469.0 | — | — | 2 | BEARISH | -9.7 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 19.6 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -9.1 | -40.0 | 3981.5 | — | — | 4 | BEARISH | 6.2 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.4 | -50.3 | 1635.6 | — | — | 1 | BEARISH | 91.2 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | BEARISH | — |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.5 | -35.4 | -415.6 | — | — | 4 | BEARISH | 43.4 |
| GLSI Greenwich LifeSciences, Inc. | $240M | -11.0 | -951.6 | 299.9 | — | — | 2 | BEARISH | 74.4 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -4.1 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BEARISH | -1.1 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.1 | -47.1 | 961.0 | — | -32.3 | 3 | BEARISH | -10.5 |
| ARVN Arvinas, Inc. | $470M | 39.1 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BEARISH | -19.1 |
| PRTA Prothena Corporation plc | $420M | -10.5 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | BEARISH | -10.3 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.2 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | BEARISH | 31.0 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| TTRX Turn Therapeutics Inc. | $310M | -36.1 | -952.4 | 115.0 | — | — | 2 | BEARISH | 105.1 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.3 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BEARISH | -16.9 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.6 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| VBIZF Viva Biotech Holdings | $400M | 13.1 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| SPRB Spruce Biosciences, Inc. | $130M | -1.1 | -106.0 | 772.2 | — | -100.0 | 4 | BEARISH | -65.7 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 22.2 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -28.7 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.1 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -17.2 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | BEARISH | 15.7 |
| BCYC Bicycle Therapeutics plc | $250M | -1.4 | -32.3 | -1197.0 | -8002.1 | 217.4 | 4 | BEARISH | -52.0 |
| CLVLF Clinuvel Pharmaceuticals Limited | $250M | 10.6 | 13.2 | 126.7 | 41.1 | -1.1 | 6 | BEARISH | -32.0 |
| CDXS Codexis, Inc. | $140M | -3.8 | -69.4 | -37.8 | -80.5 | 35.9 | 3 | BEARISH | -52.6 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 368.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 126.7 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| AURA Aura Biosciences, Inc. | $650M | -3.5 | -53.5 | -1360.0 | — | — | 4 | BEARISH | 7.5 |
| ARCT Arcturus Therapeutics Holdings Inc. | $280M | -3.4 | -46.3 | -2501.0 | -803.8 | -79.1 | 1 | BEARISH | 0.1 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| QTTB Q32 Bio Inc. | $260M | 3.1 | 72.1 | 435.2 | — | — | 5 | BEARISH | 193.3 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 1.3 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -10.9 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BEARISH | -28.1 |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | BEARISH | -64.9 |
| CAMP CAMP4 Therapeutics Corporation | $210M | -1.6 | -545.9 | 48.4 | -1884.8 | 40.2 | 2 | BEARISH | -1.9 |
| RNAC Cartesian Therapeutics, Inc. | $190M | -1.1 | 241.0 | 37.3 | — | 44.0 | 2 | BEARISH | -29.5 |
| VRXA Veraxa Biotech Holding AG | $140M | — | — | — | — | — | — | BEARISH | — |
| OTLK Outlook Therapeutics, Inc. | $130M | -0.5 | 256.9 | 1372.0 | -225766.7 | -169.4 | 3 | BEARISH | -61.9 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -5.6 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | BEARISH | 46.0 |
| ACOG Alpha Cognition Inc | $130M | -8.1 | -55.3 | -198.4 | -144.3 | 232.7 | 2 | BEARISH | 11.1 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| MGTX MeiraGTx Holdings plc | $880M | 12.3 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 7.8 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -1.6 |
| AMGXF AnGes, Inc. | $140M | -3.0 | -160.6 | -111.8 | -531.3 | -16.1 | 4 | BEARISH | 0.0 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.7 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| MNKD MannKind Corporation | $1.0B | -23.4 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | BEARISH | -38.0 |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| SABS SAB Biotherapeutics, Inc. | $260M | 0.9 | -11.3 | -48.4 | — | -100.0 | 3 | BEARISH | 1.3 |
| IMRX Immuneering Corporation | $240M | -3.7 | -52.1 | -112.8 | — | — | 4 | BEARISH | -36.6 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 466.6 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -11.2 | -1773.6 | 55.8 | — | -100.0 | 4 | BEARISH | 67.0 |
| OMER Omeros Corporation | $1.2B | 9.1 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.7 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.4 | -845.0 | 24.6 | — | — | 2 | BEARISH | 38.6 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.0 | -214.6 | 174.4 | — | — | 1 | BEARISH | 197.4 |
| MDXG MiMedx Group, Inc. | $570M | 96.6 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -42.3 |
| STTK Shattuck Labs, Inc. | $550M | -11.4 | -39.2 | -29.3 | — | -66.6 | 4 | BEARISH | 200.5 |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 4.6 |
| RZLT Rezolute, Inc. | $370M | -5.4 | -59.0 | 1060.6 | — | — | 2 | BEARISH | -55.3 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -81.5 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | BEARISH | 18.1 |
| DMTRF 3-D Matrix, Ltd. | $310M | 11.9 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
| CUE Cue Biopharma, Inc. | $140M | -0.7 | -1603.5 | 1241.9 | -1943.2 | 354.4 | 3 | BEARISH | -22.2 |
| GHRS GH Research PLC | $1.2B | -20.0 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 43.5 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.3 | -49.2 | -201.4 | — | — | 3 | BEARISH | 110.7 |
| AKTS Aktis Oncology, Inc. | $850M | -15.8 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 373763.6 |
| DSGN Design Therapeutics, Inc. | $640M | -9.1 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 85.5 |
| SLDB Solid Biosciences Inc. | $630M | -3.2 | -65.5 | -1012.6 | — | — | 3 | BEARISH | 10.1 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.8 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 24.4 |
| ANL Adlai Nortye Ltd. | $560M | -5.5 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 549.1 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.7 | -19.5 | 523.8 | — | — | 2 | BEARISH | -11.9 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 29.9 |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -21.1 |
| WHWK Whitehawk Therapeutics Inc | $180M | -3.0 | -45.0 | 963.4 | — | -100.0 | 1 | BEARISH | 38.2 |
| ANTX AN2 Therapeutics, Inc. | $130M | -3.5 | -50.1 | 1243.3 | — | — | 2 | BEARISH | 229.9 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| HBMHF HBM Holdings Limited | $1.3B | 12.5 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -5.6 | -41.0 | 583.9 | — | — | 2 | BEARISH | 2.0 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -36.8 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.8 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -4.3 |
| ALMS Alumis Inc. | $880M | -1.8 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | BEARISH | 47.2 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.5 | -55.7 | 460.5 | — | — | 3 | BEARISH | 52.9 |
| BNTC Benitec Biopharma Inc. | $300M | -8.9 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -35.5 |
| IPSC Century Therapeutics, Inc. | $260M | -1.4 | -49.7 | -60.0 | — | -100.0 | 2 | BEARISH | 151.2 |
| RCKT Rocket Pharmaceuticals, Inc. | $250M | -15.5 | -4.8 | -137.8 | — | — | 3 | BEARISH | -36.4 |
| BOVNF BioInvent International AB (publ) | $220M | -2.8 | -88.2 | 20101.5 | -964.0 | -87.2 | 1 | BEARISH | 0.0 |
| CHRS Coherus Oncology, Inc. | $160M | -1.0 | -145.4 | 1854.0 | -144.2 | -64.3 | 2 | BEARISH | -35.1 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -31.3 |
| KURA Kura Oncology, Inc. | $850M | -2.9 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BEARISH | 2.1 |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.3 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | BEARISH | 5.5 |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.5 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -5.2 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -6.9 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 29.4 |
| IRD Opus Genetics, Inc. | $290M | -2.7 | -4796.5 | 59.8 | -1072.6 | -36.1 | 3 | BEARISH | 73.9 |
| AGEN Agenus Inc. | $290M | 2.4 | -33.2 | -20.4 | -1.6 | 30.5 | 6 | BEARISH | 60.6 |
| GALT Galectin Therapeutics Inc. | $210M | -8.0 | 21.9 | 99.4 | — | — | 2 | BEARISH | -35.4 |
| CGEN Compugen Ltd. | $180M | 5.2 | 49.6 | -90.2 | -269.3 | 886.7 | 5 | BEARISH | 9.4 |
| MGNX MacroGenics, Inc. | $140M | -10.8 | -32.6 | 33.8 | 59.4 | 2.3 | 2 | BEARISH | 32.6 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 219.4 |
| MDCLF MedinCell S.A. | $1.1B | -29.2 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| IMMX Immix Biopharma, Inc. | $680M | -9.3 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 123.0 |
| CADL Candel Therapeutics, Inc. | $610M | -5.9 | -81.8 | 219.4 | — | — | 2 | BEARISH | 52.8 |
| CLYM Climb Bio, Inc. | $590M | -11.6 | -27.1 | -88.6 | — | — | 2 | BEARISH | 380.9 |
| GNFTF Genfit S.A. | $470M | -5.2 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| AVCTF Avacta Group Plc | $420M | -6.7 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| IKT Inhibikase Therapeutics, Inc. | $220M | -3.3 | -52.0 | 920.5 | — | — | 3 | BEARISH | 1.9 |
| PLX Protalix BioTherapeutics, Inc. | $210M | 10.5 | 31.2 | 47.1 | 19.0 | 30.1 | 5 | BEARISH | 7.2 |
| PRQR ProQR Therapeutics N.V. | $180M | -3.0 | -57.9 | 139.7 | -99.6 | 12.7 | 2 | BEARISH | -54.0 |
| ORMP Oramed Pharmaceuticals Inc. | $170M | 1.0 | 74.1 | -4.3 | — | -100.0 | 4 | BEARISH | 74.1 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.4 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 1.2 |
| ARDX Ardelyx, Inc. | $770M | -13.2 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -40.5 |
| GERN Geron Corporation | $720M | -11.5 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -7.3 |
| SANA Sana Biotechnology, Inc. | $700M | -3.2 | -152.9 | -242.3 | — | — | 3 | BEARISH | -55.8 |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| WVE Wave Life Sciences Ltd. | $630M | -3.2 | -80.0 | -1243.7 | -470.5 | -35.1 | 4 | BEARISH | -51.6 |
| GYRE Gyre Therapeutics, Inc. | $620M | -32.8 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | BEARISH | -20.1 |
| ANNX Annexon, Inc. | $610M | -3.2 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 17.1 |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.3 | -52.7 | 585.3 | — | — | 2 | BEARISH | -12.3 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.2 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.1 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.7 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -59.1 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.6 | -57.5 | -366.6 | — | — | 2 | BEARISH | — |
| SPHDF Santhera Pharmaceuticals Holding AG | $280M | -6.6 | 729.6 | 111.3 | -44.5 | 106.3 | 7 | BEARISH | 49.1 |
| VOGX Vogenx Inc. | $260M | — | — | — | — | — | — | BEARISH | — |
| ORYZF Oryzon Genomics S.A. | $250M | -80.4 | -3.0 | -7.2 | -1.6 | 12.6 | 4 | BEARISH | -14.1 |
| LRMR Larimar Therapeutics, Inc. | $240M | -1.2 | -139.6 | 590.9 | — | — | 2 | BEARISH | -43.2 |
| HLOSF Healios K.K. | $240M | 56.3 | 3.7 | -129.2 | 17028.6 | -47.1 | 4 | BEARISH | -48.6 |
| VNDA Vanda Pharmaceuticals Inc. | $240M | -0.9 | -77.8 | -201.0 | -123.7 | 6.0 | 3 | BEARISH | -27.4 |
| LXEO Lexeo Therapeutics, Inc. Common Stock | $230M | -2.5 | -46.8 | -249.1 | — | — | 3 | BEARISH | -68.9 |
| IPHYF Innate Pharma S.A. | $210M | -2.5 | 267.9 | 119.2 | -343.8 | 32.0 | 3 | BEARISH | -24.5 |
| BBOT BridgeBio Oncology Therapeutics Inc. | $210M | -0.0 | -56.4 | -157.3 | — | — | 1 | BEARISH | -75.5 |
| EVMN Evommune, Inc. | $190M | -1.5 | -29.6 | -82.4 | — | — | 2 | BEARISH | — |
| BIOA BioAge Labs Inc. | $190M | -2.3 | -28.2 | -142.3 | -1064.7 | 168.1 | 4 | BEARISH | -28.0 |
| ELDN Eledon Pharmaceuticals, Inc. | $190M | -2.4 | -110.7 | 411.1 | — | — | 2 | BEARISH | -30.8 |
| AKBA Akebia Therapeutics, Inc. | $160M | -6.1 | -109.4 | 15.6 | -18.1 | 7.5 | 6 | BEARISH | -78.2 |
| ZNTL Zentalis Pharmaceuticals, Inc. | $160M | -0.8 | -83.7 | -2245.4 | — | -100.0 | 2 | BEARISH | 15.8 |
| NBP NovaBridge Biosciences | $160M | -2.2 | -45.7 | -617.8 | — | — | 1 | BEARISH | -70.4 |
| NGEN NervGen Pharma Corp. Common stock | $150M | — | — | — | — | — | — | BEARISH | — |
| MDWD MediWound Ltd. | $150M | -7.7 | -72.4 | -255.1 | -239.1 | -40.3 | 2 | BEARISH | -31.9 |
| TARA Protara Therapeutics, Inc. | $140M | -1.8 | -45.8 | -41.3 | — | — | 2 | BEARISH | -51.6 |
| NKTX Nkarta, Inc. | $130M | -1.1 | -38.8 | -75.4 | — | — | 1 | BEARISH | -15.0 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $130M | — | — | — | — | — | — | BEARISH | -96.9 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.1 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -18.3 |
| SVRA Savara Inc. | $870M | -8.4 | -105.5 | -15438.9 | — | — | 2 | BEARISH | 11.5 |
| IVEVF Inventiva S.A. | $750M | -6.2 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| ATTO Attovia Therapeutics, Inc. | $630M | -15.3 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 272.2 |
| PROK ProKidney Corp. | $470M | -2.7 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.5 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.7 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -55.7 |
| RGNX REGENXBIO Inc. | $440M | -1.7 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -49.4 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.9 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 2.5 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -46.0 |
| ASMB Assembly Biosciences, Inc. | $400M | 37.0 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -30.6 |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 18.6 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -61.6 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | -1.6 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -1.9 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.3 |
| FULC Fulcrum Therapeutics, Inc. | $280M | -3.1 | -32.4 | 2389.1 | — | — | 4 | BEARISH | -59.9 |
| CTNM Contineum Therapeutics, Inc. | $270M | -5.2 | -28.0 | -541.6 | — | — | 4 | BEARISH | -18.6 |
| ABEO Abeona Therapeutics Inc. | $250M | -3.9 | -43.1 | -5983.3 | -177.4 | 6280.0 | 2 | BEARISH | -18.8 |
| CABA Cabaletta Bio, Inc. | $250M | -0.9 | -93.2 | -1308.0 | — | — | 3 | BEARISH | -40.9 |
| SCTX Scribe Therapeutics Inc. | $250M | — | — | — | — | — | — | BEARISH | — |
| OCGN Ocugen, Inc. | $250M | -2.9 | 1211.7 | 190.2 | -1671.8 | -3.7 | 2 | BEARISH | -52.4 |
| ACIU AC Immune S.A. | $250M | -4.2 | -78.5 | 96.7 | 12.4 | -39.5 | 2 | BEARISH | -30.8 |
| PALI Palisade Bio, Inc. | $230M | -2.3 | -51.4 | 815.6 | -2114.8 | — | 5 | BEARISH | -31.0 |
| NAGE Niagen Bioscience Inc | $190M | 12.9 | 21.8 | 44.7 | 3.2 | 11.0 | 6 | BEARISH | -67.0 |
| IVVD Invivyd, Inc. | $180M | -1.5 | -95.9 | -302.5 | -310.8 | 26.3 | 2 | BEARISH | -73.2 |
| SION Sionna Therapeutics, Inc. | $160M | -1.8 | -32.3 | -137.7 | — | — | 0 | BEARISH | -90.1 |
| CNTN Canton Strategic Holdings Inc | $150M | -1.2 | -14.6 | -7.2 | -1287.2 | — | 2 | BEARISH | — |
| UPB Upstream Bio, Inc. | $150M | -1.0 | -46.0 | -1266.4 | -5136.1 | 49.2 | 3 | BEARISH | -83.0 |
| STRO Sutro Biopharma, Inc. | $150M | -0.5 | 266.8 | 43.6 | -391.6 | -56.3 | 4 | BEARISH | -15.5 |
| CMPX Compass Therapeutics, Inc. | $140M | -1.8 | -56.7 | 1526.3 | — | — | 4 | BEARISH | -81.2 |
| EDIT Editas Medicine, Inc. | $370M | -3.4 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BEARISH | -30.1 |
| MOBI Mobia Medical, Inc. Common Stock | $350M | — | — | — | — | — | — | BULLISH | — |
| RCEL Avita Medical Inc. | $390M | -11.0 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 305.0 |
| AVHHL AVITA Medical, Inc. | $360M | -11.0 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 149.1 |
| CV CapsoVision, Inc. | $370M | -10.7 | -226.6 | -73.0 | -205.4 | — | 2 | BULLISH | 37.8 |
| VMD Viemed Healthcare, Inc. | $370M | 25.7 | 10.2 | 11.8 | 3.5 | 25.2 | 4 | BULLISH | 39.9 |
| IDGXF Integrated Diagnostics Holdings plc | $340M | 10.4 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BULLISH | 10.8 |
| SI Shoulder Innovations, Inc. | $410M | -11.6 | -28.2 | -69.1 | -59.1 | — | 1 | BULLISH | 57.7 |
| EMBC Embecta Corp. | $380M | 4.4 | -13.6 | 26.3 | 7.8 | -7.6 | 5 | BULLISH | -53.7 |
| VHIBF Vitalhub Corp. | $340M | 62.2 | 3.3 | 10.7 | 6.1 | 53.9 | 7 | BULLISH | -31.4 |
| CARL Carlsmed, Inc. | $400M | -11.5 | -43.8 | -122.7 | -55.5 | — | 2 | BULLISH | 14.4 |
| CSSPF NIOX Group Plc | $380M | 41.3 | 10.8 | 13.0 | 24.6 | 3.5 | 7 | NEUTRAL | -2.3 |
| OFIX Orthofix Medical Inc. | $400M | -6.4 | -13.9 | -3.6 | -7.5 | 3.0 | 6 | NEUTRAL | -39.2 |
| SRTA Strata Critical Medical, Inc. | $410M | 9.5 | 16.0 | -6.2 | -14.5 | 0.6 | 3 | LEAN BEAR | -6.2 |
| AUNA Auna S.A. | $380M | -17.4 | 0.8 | 4.5 | 2.4 | 9.2 | 7 | LEAN BEAR | -21.1 |
| CTEV Claritev Corporation | $400M | -1.4 | 169.3 | 0.9 | -23.0 | 110.3 | 4 | BEARISH | -67.5 |
| TKNO Alpha Teknova, Inc. | $340M | -22.4 | -24.2 | -17.2 | -26.0 | 12.3 | 4 | BEARISH | 25.2 |
| VRNO Verano Holdings Corp | $370M | -1.4 | -4.5 | 1.5 | -6.0 | — | 3 | BEARISH | — |
| SWDCF Swedencare AB (publ) | $370M | 35.2 | 1.2 | 1.7 | 3.9 | 1.4 | 7 | BEARISH | -46.5 |
| SENS Senseonics Holdings, Inc. | $400M | -3.7 | -118.2 | -901.4 | -253.4 | 79.0 | 3 | BEARISH | 18.8 |
| NIKA Nika Pharmaceuticals Inc. | $370M | -4711.6 | 26.8 | 18.5 | — | 100.0 | 3 | BEARISH | 8.5 |
| EDIT Editas Medicine, Inc. | $370M | -3.4 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BEARISH | -30.1 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.7 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 32.8 |
| ALKS Alkermes plc | $7.3B | 110.1 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 48.7 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 43.0 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 103.2 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.9 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 5.8 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.7 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 92.0 |
| LFST LifeStance Health Group, Inc. | $4.9B | 101.0 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 151.9 |
| ATRC AtriCure, Inc. | $3.0B | 289.6 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.9 |
| GNNDY GN Store Nord A/S | $2.4B | -29.9 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -5.1 |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| AMN AMN Healthcare Services, Inc. | $1.9B | 17.2 | 15.6 | 8.9 | 3.1 | 24.0 | 8 | BULLISH | 120.8 |
| HCSG Healthcare Services Group, Inc. | $1.7B | 16.0 | 20.4 | 27.0 | 5.2 | 4.0 | 7 | BULLISH | 31.8 |
| ARDT Ardent Health Inc. | $1.7B | 21.6 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BULLISH | -22.3 |
| CERT Certara, Inc. | $1.6B | -24.5 | -6.7 | 0.6 | -59.3 | 0.7 | 6 | BULLISH | -13.5 |
| MRCHF H.U. Group Holdings, Inc. | $1.3B | 22.0 | 7.2 | 3.3 | 2.5 | 1.8 | 9 | BULLISH | -7.4 |
| LTGHY Life Healthcare Group Holdings Limited | $1.1B | 2.7 | 68.5 | 10.7 | 6.2 | -3.0 | 4 | BULLISH | 14.5 |
| HSTM HealthStream, Inc. | $1.1B | 47.8 | 6.0 | 6.5 | 8.0 | 8.8 | 8 | BULLISH | 30.1 |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| VSTM Verastem, Inc. | $910M | -4.1 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 27.0 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -15.8 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| MOBI Mobia Medical, Inc. Common Stock | $350M | — | — | — | — | — | — | BULLISH | — |
| HNGE Hinge Health, Inc. | $9.0B | 84.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 129.6 |
| HQY HealthEquity, Inc. | $8.6B | 36.3 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 4.5 |
| PACS PACS Group, Inc. | $7.5B | 28.0 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 277.8 |
| SSMXY Sysmex Corporation | $7.4B | 30.7 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.5 |
| DOCS Doximity, Inc. | $6.0B | 37.2 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.3 |
| WAY Waystar Holding Corp. | $5.5B | 38.9 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -28.1 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.7 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.4 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 27.8 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | 1.8 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.7 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 64.0 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| PGNY Progyny, Inc. | $2.2B | 28.5 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 42.2 |
| PRGO Perrigo Company plc | $2.2B | -1.3 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -23.7 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 78.2 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 28.9 |
| GDRX GoodRx Holdings, Inc. | $1.2B | 65.6 | 2.5 | 3.5 | 4.3 | -1.8 | 6 | BULLISH | -11.9 |
| CBLL CeriBell, Inc. | $1.0B | -15.5 | -43.9 | -263.7 | -68.6 | 69.3 | 3 | BULLISH | 111.2 |
| BVS Bioventus Inc. | $1.0B | 18.1 | 28.0 | 21.3 | 21.8 | 3.1 | 7 | BULLISH | 107.8 |
| CTKB Cytek Biosciences, Inc. | $730M | -9.6 | -23.0 | -40.8 | -25.3 | 5.4 | 3 | BULLISH | 40.4 |
| KIDS OrthoPediatrics Corp. | $640M | -14.3 | -11.4 | -4.6 | -10.2 | 14.5 | 6 | BULLISH | 39.9 |
| AONC American Oncology Network, Inc. | $640M | -29.7 | 5.6 | -14.7 | 0.3 | 37.5 | 6 | BULLISH | 132.2 |
| EVH Evolent Health, Inc. | $540M | -1.0 | -79.0 | -1.8 | -4.3 | -4.5 | 5 | BULLISH | -43.4 |
| ENTX Entera Bio Ltd. | $510M | -8.8 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 37.8 |
| RCEL Avita Medical Inc. | $390M | -11.0 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 305.0 |
| SGRY Surgery Partners, Inc. | $2.1B | -33.7 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 2.4 |
| OMCL Omnicell, Inc. | $1.7B | 42.8 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | BULLISH | 18.2 |
| LWSCF Sienna Senior Living Inc. | $1.6B | 38.9 | 6.7 | 3.9 | 4.4 | 16.2 | 7 | BULLISH | 7.9 |
| PHR Phreesia, Inc. | $790M | 71.5 | 3.1 | 16.7 | 1.5 | 12.9 | 4 | BULLISH | -47.7 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.7 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -14.5 |
| BLCO Bausch + Lomb Corporation | $6.2B | -36.9 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 13.5 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| TNDM Tandem Diabetes Care, Inc. | $1.2B | -20.6 | -48.0 | -8.2 | -8.3 | -7.1 | 4 | BULLISH | 28.6 |
| STAA STAAR Surgical Company | $1.1B | 301.5 | 1.1 | 3.5 | 8.6 | 51.3 | 5 | BULLISH | -8.0 |
| LMRI Lumexa Imaging Holdings, Inc. Common Stock | $1.1B | -31.0 | -3.9 | 0.1 | 1.0 | — | 3 | BULLISH | — |
| NRC NRC Health | $490M | 82.2 | 42.0 | 9.9 | -9.3 | -0.2 | 6 | BULLISH | 48.3 |
| KRRO Korro Bio, Inc. | $180M | -1.3 | -97.7 | -196.6 | — | -62.1 | 2 | BULLISH | -65.1 |
| HURA TuHURA Biosciences, Inc. | $140M | -3.8 | -161.4 | -137.6 | — | — | 2 | BULLISH | -7.9 |
| AVHHL AVITA Medical, Inc. | $360M | -11.0 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 149.1 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| GRRMF Gerresheimer AG | $1.2B | -2.8 | 1.6 | 2.2 | -2.3 | 11.8 | 4 | BULLISH | -27.1 |
| QDEL QuidelOrtho Corporation | $940M | -0.9 | -45.9 | -13.7 | -14.7 | 0.1 | 4 | BULLISH | -55.5 |
| TDVXF Dynavox Group AB (publ) | $900M | 27.8 | 39.7 | 17.2 | 12.8 | 8.8 | 8 | BULLISH | -22.7 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -41.1 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 52.7 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.1 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| VCYT Veracyte, Inc. | $3.9B | 35.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -44.9 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 194.2 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.1 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -26.2 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.6 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BULLISH | 34.7 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.9 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| SAEYY Redcare Pharmacy N.V. | $1.7B | -37.3 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -5.2 |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | -11.3 | -73.7 | -113.5 | -142.3 | 191.6 | 3 | BULLISH | 15.3 |
| AGL Agilon Health, Inc. | $1.5B | -5.9 | -78.9 | -273.7 | 1.2 | 0.3 | 6 | BULLISH | 273.6 |
| PNTG The Pennant Group, Inc. | $1.5B | 44.1 | 9.6 | 5.5 | 3.0 | 37.9 | 6 | BULLISH | 72.8 |
| PCRX Pacira BioSciences, Inc. | $1.4B | 103.4 | 2.0 | 1.8 | 2.4 | 5.7 | 8 | BULLISH | 67.4 |
| NWKHY Netcare Limited | $1.4B | 12.5 | 16.9 | 8.1 | 6.7 | 5.0 | 7 | BULLISH | 59.5 |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 511.8 | -1.3 | 7.7 | 0.7 | 17.1 | 5 | BULLISH | -3.7 |
| ENOV Enovis Corporation | $1.2B | -1.1 | -54.3 | -13.5 | -0.2 | 4.9 | 4 | BULLISH | -34.4 |
| TDOC Teladoc Health, Inc. | $1.1B | -6.4 | -13.0 | -8.7 | -6.4 | -2.1 | 5 | BULLISH | -31.8 |
| ARRJF Arjo AB (publ) | $920M | 25.3 | 4.6 | 4.4 | 2.0 | -2.0 | 6 | BULLISH | 3.1 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.8 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 68.7 |
| IOBCF Ion Beam Applications S.A. | $550M | 19.7 | 20.6 | 14.0 | 2.9 | 7.0 | 5 | BULLISH | 39.5 |
| CV CapsoVision, Inc. | $370M | -10.7 | -226.6 | -73.0 | -205.4 | — | 2 | BULLISH | 37.8 |
| VMD Viemed Healthcare, Inc. | $370M | 25.7 | 10.2 | 11.8 | 3.5 | 25.2 | 4 | BULLISH | 39.9 |
| IDGXF Integrated Diagnostics Holdings plc | $340M | 10.4 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BULLISH | 10.8 |
| PACB Pacific Biosciences of California, Inc. | $660M | -5.8 | -929.3 | -29.4 | -114.7 | 2.0 | 2 | BULLISH | 21.3 |
| GNGBY Getinge AB (publ) | $7.3B | 25.9 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.6 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.4 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.6 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -2.0 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| TGLVY Top Glove Corporation Bhd. | $1.7B | 25.1 | 6.3 | 8.5 | 12.6 | 21.4 | 8 | BULLISH | 51.4 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.4 | -25.8 | -768.9 | — | — | 2 | BULLISH | 148.2 |
| SIBN SI-BONE, Inc. | $960M | -63.3 | -8.3 | -32.2 | -7.3 | 15.3 | 6 | BULLISH | 38.4 |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 171.0 |
| KHTRF Knight Therapeutics Inc. | $810M | 76.5 | 1.9 | 2.6 | -2.3 | 42.4 | 8 | BULLISH | 98.5 |
| PBYI Puma Biotechnology, Inc. | $570M | 20.3 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 108.8 |
| MXCT MaxCyte, Inc. | $140M | -4.7 | -20.4 | -38.9 | -122.0 | -13.2 | 2 | BULLISH | -5.5 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| OPK OPKO Health, Inc. | $1.2B | -16.8 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | BULLISH | 7.3 |
| MYGN Myriad Genetics, Inc. | $560M | -5.3 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -22.8 |
| AZTA Azenta, Inc. | $1.6B | -14.3 | -7.7 | -1.4 | 1.5 | 1.5 | 4 | BULLISH | 21.1 |
| AHG Akso Health Group | $1.1B | -20.2 | -50.1 | -44.9 | -546.5 | 22.7 | 4 | BULLISH | -17.1 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 29.5 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 14.7 |
| PRCT PROCEPT BioRobotics Corporation | $1.1B | -10.2 | -30.2 | -47.6 | -28.4 | 22.7 | 2 | BULLISH | -43.4 |
| BBNX Beta Bionics, Inc. | $860M | -13.0 | -26.2 | -79.6 | -73.1 | 191.1 | 3 | BULLISH | 2.1 |
| PHAR Pharming Group N.V. | $710M | 81.8 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -12.7 |
| TCMD Tactile Systems Technology, Inc. | $540M | 21.4 | 11.9 | 13.8 | 9.1 | 17.2 | 8 | BULLISH | 55.4 |
| SI Shoulder Innovations, Inc. | $410M | -11.6 | -28.2 | -69.1 | -59.1 | — | 1 | BULLISH | 57.7 |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -8.8 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -17.1 |
| HAE Haemonetics Corporation | $5.4B | 58.5 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 134.1 |
| CDNA CareDx, Inc | $3.6B | 32.8 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 371.1 |
| OABIW OmniAb, Inc. | $1.1B | -13.8 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -17.6 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -11.9 | -114.6 | 616.3 | — | — | 2 | BULLISH | 26.3 |
| SCNLF Scancell Holdings plc | $170M | -5.1 | 153.2 | 179.2 | — | -100.0 | 2 | BULLISH | 969.8 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.7 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -1.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.1 |
| AMBBY Ambu A/S | $3.2B | 41.6 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.1 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -16.0 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.2 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| VTRLY Vitrolife AB (publ) | $1.4B | -3.1 | -46.2 | -41.3 | 14.3 | -2.0 | 5 | BULLISH | -34.0 |
| EMBC Embecta Corp. | $380M | 4.4 | -13.6 | 26.3 | 7.8 | -7.6 | 5 | BULLISH | -53.7 |
| CASBF CanSino Biologics Inc. | $1.4B | 367.7 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BULLISH | -25.5 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BULLISH | — |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| PAHC Phibro Animal Health Corporation | $1.6B | 15.7 | 29.7 | 13.2 | 5.5 | 17.1 | 7 | BULLISH | -9.1 |
| CRMD CorMedix Inc. | $610M | 3.3 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -28.4 |
| VHIBF Vitalhub Corp. | $340M | 62.2 | 3.3 | 10.7 | 6.1 | 53.9 | 7 | BULLISH | -31.4 |
| TCHBF Tecan Group AG | $3.5B | -26.5 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | BULLISH | 45.2 |
| ASTH Astrana Health, Inc. | $1.9B | 44.5 | 5.1 | 4.7 | 2.0 | 58.9 | 5 | BULLISH | 10.9 |
| MASS 908 Devices Inc. | $470M | -13.3 | -25.1 | -103.8 | -74.0 | 4.6 | 5 | BULLISH | 45.2 |
| ADCT ADC Therapeutics S.A. | $180M | -2.4 | 45.3 | 260.9 | -86.1 | 2.0 | 2 | BULLISH | -61.1 |
| GRAL GRAIL Inc. | $5.9B | -15.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 68.5 |
| EKTAY Elekta AB (publ) | $2.2B | -60.9 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 9.3 |
| PRME Prime Medicine, Inc. | $670M | -4.0 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | -18.4 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $460M | 75.9 | 1.9 | -0.5 | -19.7 | 66.6 | 4 | BULLISH | -17.1 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.5 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 136.9 |
| BLLN BillionToOne, Inc. | $5.1B | 166.9 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| COLL Collegium Pharmaceutical, Inc. | $750M | 15.0 | 17.6 | 9.4 | -7.5 | 14.3 | 6 | BULLISH | -34.8 |
| CARL Carlsmed, Inc. | $400M | -11.5 | -43.8 | -122.7 | -55.5 | — | 2 | BULLISH | 14.4 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| LMAT LeMaitre Vascular, Inc. | $1.9B | 29.1 | 16.8 | 25.6 | 24.2 | 11.8 | 8 | BULLISH | -5.8 |
| INNV Innovage Holding Corp. | $1.3B | -439.5 | -1.1 | -89.6 | 3.2 | 16.4 | 6 | BULLISH | 73.1 |
| CSWYF China Shineway Pharmaceutical Group Limited | $760M | 6.0 | 19.9 | 46.7 | 21.6 | 1081.8 | 8 | BULLISH | 0.0 |
| ICUI ICU Medical, Inc. | $4.2B | 136.5 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BULLISH | 32.2 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | -0.3 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| CNMD CONMED Corporation | $1.5B | 25.3 | 5.5 | 5.2 | 6.7 | 3.4 | 7 | BULLISH | -1.3 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| GMRS GMR Solutions Inc. | $580M | — | — | — | — | — | — | BULLISH | — |
| SHWGF Shandong Weigao Group Medical Polymer Company Limited | $1.9B | 9.3 | 5.6 | 7.4 | 11.3 | 2.2 | 6 | BULLISH | -39.1 |
| ESTA Establishment Labs Holdings Inc. | $1.9B | -51.5 | -175.3 | -6.9 | -17.4 | 38.6 | 5 | BULLISH | 36.4 |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | BULLISH | -48.2 |
| CHE Chemed Corporation | $6.7B | 25.4 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BULLISH | 16.6 |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| SGHT Sight Sciences, Inc. | $500M | -16.1 | -48.4 | -145.7 | -19.0 | 9.3 | 4 | BULLISH | 71.0 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.9 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| CRON Cronos Group Inc. | $1.2B | 18.0 | 6.5 | 5.4 | 60.5 | 72.9 | 7 | BULLISH | 34.1 |
| SLGL Sol-Gel Technologies Ltd. | $230M | -12.4 | -35.9 | -228.0 | 36.4 | 282.9 | 3 | BULLISH | 74.8 |
| HCM HUTCHMED (China) Limited | $2.6B | 149.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BULLISH | -6.5 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| AORT Artivion, Inc. | $1.1B | -386.5 | -0.7 | -3.4 | -10.7 | 16.4 | 4 | BULLISH | -47.1 |
| CYDY CytoDyn Inc. | $380M | -4.9 | 57.8 | 24.6 | — | 100.0 | 4 | BULLISH | -16.2 |
| SHC Sotera Health Company | $5.2B | 32.2 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 9.7 |
| SOPH SOPHiA GENETICS S.A. | $630M | -6.7 | -101.2 | -155.2 | -95.9 | 23.6 | 3 | LEAN BULL | 77.4 |
| CYH Community Health Systems, Inc. | $410M | -1.2 | 19.9 | -79.1 | 1.7 | 77.2 | 5 | LEAN BULL | -30.7 |
| ABOS Acumen Pharmaceuticals, Inc. | $140M | -1.5 | -162.7 | 466.8 | — | — | 2 | LEAN BULL | 2.3 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 69.3 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | LEAN BULL | -15.2 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 142.2 |
| XRAY DENTSPLY SIRONA Inc. | $1.9B | -3.4 | -33.0 | 9.9 | 4.1 | -0.8 | 5 | LEAN BULL | -27.6 |
| COGZF Cogstate Limited | $410M | 34.6 | 22.4 | 37.3 | 22.4 | -14.8 | 3 | LEAN BULL | 44.9 |
| PTCHF PureTech Health plc | $390M | 157.1 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | LEAN BULL | -5.4 |
| SGMT Sagimet Biosciences Inc. | $310M | -8.2 | -24.4 | -231.4 | — | — | 3 | LEAN BULL | 14.0 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.5 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.4 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.2 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -7.9 |
| TSMRF Tsumura & Co. | $1.7B | 9.2 | 9.9 | 6.6 | 13.0 | 10.7 | 4 | LEAN BULL | 0.0 |
| SWGHF Sawai Group Holdings Co., Ltd. | $1.3B | 22.7 | 4.3 | 4.6 | 4.7 | 11.4 | 4 | LEAN BULL | 0.0 |
| TWAPF Towa Pharmaceutical Co., Ltd. | $1.3B | 21.1 | 4.7 | 3.2 | 7.7 | 7.1 | 7 | LEAN BULL | 54.4 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $980M | 14.0 | 6.9 | 7.9 | 28.0 | -6.6 | 4 | LEAN BULL | 8.3 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BULL | 62.6 |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.1 | -67.4 | 2902.7 | — | — | 1 | LEAN BULL | 25.3 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.6 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | LEAN BULL | 12.1 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 388.6 |
| NVST Envista Holdings Corp | $3.8B | 40.2 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 15.9 |
| HUMDF Hua Medicine (Shanghai) Ltd. | $300M | -17.8 | -10.3 | -30.2 | -8.0 | 73.9 | 3 | LEAN BULL | -26.1 |
| PMI Picard Medical, Inc. | $730M | -0.3 | -1631.2 | -469.0 | -191.6 | — | 2 | LEAN BULL | 28.2 |
| CERS Cerus Corporation | $470M | -67.3 | -10.8 | -7.4 | -5.1 | 15.1 | 5 | LEAN BULL | 56.9 |
| AHCO AdaptHealth Corp. | $820M | -3.5 | -15.5 | -0.2 | -18.1 | 22.9 | 6 | LEAN BULL | -37.6 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.2 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BULL | -23.8 |
| HSTC HST Global, Inc. | $210M | -538.5 | -2.5 | -1.2 | -13.7 | 564.0 | 5 | LEAN BULL | 349900.0 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | LEAN BULL | -33.0 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | LEAN BULL | -5.9 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| LCTX Lineage Cell Therapeutics, Inc. | $250M | -7.3 | -59.0 | -171.3 | 138.6 | 19.9 | 5 | LEAN BULL | -39.4 |
| NEOG Neogen Corporation | $2.7B | -49.3 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.5 |
| ATEC Alphatec Holdings, Inc. | $1.7B | -15.2 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | LEAN BULL | -32.5 |
| IUSDF AS ONE Corporation | $1.0B | 19.2 | 12.2 | 13.4 | 8.1 | 5.7 | 6 | LEAN BULL | -39.5 |
| MLAB Mesa Laboratories, Inc. | $720M | 150.7 | 2.7 | 4.4 | 4.7 | 3.0 | 8 | LEAN BULL | 63.6 |
| BRKR Bruker Corporation | $8.8B | -86.2 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | NEUTRAL | 55.9 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| NPNKF Nippon Shinyaku Co., Ltd. | $1.6B | 7.2 | 11.6 | 12.5 | 20.6 | 12.8 | 4 | NEUTRAL | -1.1 |
| CSTL Castle Biosciences, Inc. | $1.0B | -52.0 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | NEUTRAL | 40.8 |
| KMDA Kamada Ltd. | $450M | 21.0 | 8.4 | 11.0 | 16.9 | 13.2 | 7 | NEUTRAL | 17.2 |
| LYEL Lyell Immunopharma, Inc. | $230M | -0.6 | -93.3 | -227.7 | -1118875.0 | -55.0 | 3 | NEUTRAL | -42.6 |
| PRLD Prelude Therapeutics Incorporated | $210M | -4.9 | -57.7 | 14236.3 | -244.1 | 220.3 | 5 | NEUTRAL | 139.5 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -9.5 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | NEUTRAL | 73.8 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 88.5 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 32.6 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.6 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | NEUTRAL | -13.4 |
| SGIPF Sugi Holdings Co.,Ltd. | $1.8B | 15.5 | 10.0 | 11.6 | 2.2 | 46.6 | 7 | NEUTRAL | 0.9 |
| SAFLY Safilo Group S.p.A. | $1.4B | 15.4 | 12.0 | 10.0 | 8.7 | -3.4 | 7 | NEUTRAL | 40.1 |
| VREX Varex Imaging Corporation | $780M | 35.1 | 4.6 | 7.6 | 7.5 | 5.3 | 6 | NEUTRAL | 54.0 |
| CSSPF NIOX Group Plc | $380M | 41.3 | 10.8 | 13.0 | 24.6 | 3.5 | 7 | NEUTRAL | -2.3 |
| NWBO Northwest Biotherapeutics, Inc. | $260M | -6.7 | 55.8 | -188.7 | -1142.6 | 98.6 | 3 | NEUTRAL | -33.7 |
| MLLCF Molecular Partners AG | $150M | -2.3 | -62.1 | 650.3 | — | -100.0 | 2 | NEUTRAL | 14.6 |
| REPL Replimune Group, Inc. | $1.1B | -4.2 | -134.3 | -1055.2 | — | — | 1 | NEUTRAL | 48.3 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| OFIX Orthofix Medical Inc. | $400M | -6.4 | -13.9 | -3.6 | -7.5 | 3.0 | 6 | NEUTRAL | -39.2 |
| CTY City Therapeutics Inc. | $200M | — | — | — | — | — | — | N/A | — |
| IAM Iambic Therapeutics Inc. | $130M | — | — | — | — | — | — | N/A | — |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 19.2 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| RKAGY RHÃN-KLINIKUM Aktiengesellschaft | $1.1B | 22.3 | 2.8 | 3.1 | 2.1 | 2.5 | 6 | NEUTRAL | 10.7 |
| SRZN Surrozen, Inc. | $190M | -0.7 | 387.2 | 11.1 | 1003.5 | -8.8 | 2 | NEUTRAL | 114.8 |
| YARW Yarrow Bioscience Inc | $180M | — | — | — | — | — | — | NEUTRAL | — |
| VCRE Vicore Pharma Holding AB | $260M | — | — | — | — | — | — | NEUTRAL | — |
| KROS Keros Therapeutics, Inc. | $220M | -3.1 | -17.2 | -392.2 | — | -93.6 | 3 | NEUTRAL | -24.0 |
| AXGN AxoGen, Inc. | $2.2B | -56.1 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | NEUTRAL | 106.2 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| AMPH Amphastar Pharmaceuticals, Inc. | $1.1B | 14.6 | 10.3 | 7.5 | 16.5 | 1.4 | 6 | NEUTRAL | 4.3 |
| JNDOF JINS HOLDINGS Inc. | $810M | 17.8 | 22.7 | 27.1 | 5.1 | 15.0 | 6 | LEAN BEAR | 51.6 |
| MCTA Charming Medical Limited Class A Ordinary Shares | $450M | — | — | — | — | — | — | LEAN BEAR | — |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | LEAN BEAR | — |
| GEDSF Gedeon Richter PLC | $4.5B | 10.7 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| OSSFF Embla Medical hf. | $1.9B | 18.0 | 10.4 | 7.7 | 10.5 | 9.9 | 7 | LEAN BEAR | -5.6 |
| STSEY Stratec SE | $1.7B | -575.0 | -0.2 | -0.2 | 7.0 | -4.8 | 4 | LEAN BEAR | -17.8 |
| AGYTF Allergy Therapeutics plc | $760M | -4.3 | 3372.3 | -97.9 | -54.9 | 19.9 | 3 | LEAN BEAR | 36.4 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | LEAN BEAR | -25.4 |
| RDNT RadNet, Inc. | $5.5B | -277.5 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | LEAN BEAR | -11.8 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 111.6 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.1 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | LEAN BEAR | -24.8 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 14.8 | 20.0 | 20.7 | 9.3 | 30.9 | 7 | LEAN BEAR | -24.5 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | LEAN BEAR | 18.2 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 174.6 |
| NUTX Nutex Health, Inc. | $1.4B | 7.8 | 49.2 | 53.9 | 31.2 | 6.9 | 7 | LEAN BEAR | 65.8 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| PSNL Personalis, Inc. | $1.7B | -14.7 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | LEAN BEAR | 65.1 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $540M | 10.3 | 20.8 | 23.4 | 32.9 | 697.9 | 9 | LEAN BEAR | 0.0 |
| RSLBF RaySearch Laboratories AB (publ) | $510M | 31.8 | 26.1 | 21.8 | 7.2 | 1.2 | 6 | LEAN BEAR | -35.8 |
| DTIL Precision BioSciences, Inc. | $180M | -2.4 | -135.1 | 203.1 | — | 3473.0 | 5 | LEAN BEAR | 1.0 |
| PEPG PepGen Inc. | $170M | -1.7 | -75.5 | -327.5 | — | — | 4 | LEAN BEAR | -43.1 |
| JBIO Jade Biosciences, Inc. | $930M | -5.4 | -47.8 | 629.9 | — | — | 3 | LEAN BEAR | 47.4 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BEAR | 76.3 |
| SRTA Strata Critical Medical, Inc. | $410M | 9.5 | 16.0 | -6.2 | -14.5 | 0.6 | 3 | LEAN BEAR | -6.2 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.6 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| MDRSF Medartis Holding AG | $1.4B | 78.9 | 5.5 | 0.7 | 3.2 | 29.6 | 6 | LEAN BEAR | 72.5 |
| KRSA Korsana Biosciences, Inc. | $150M | — | — | — | — | — | — | LEAN BEAR | — |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.9 | -45.3 | -2390.9 | — | — | 2 | LEAN BEAR | 51.2 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | LEAN BEAR | 14.2 |
| LJUIF SSY Group Limited | $1.2B | 15.2 | 6.7 | 4.6 | 13.6 | -4.4 | 5 | LEAN BEAR | 0.0 |
| SHEZF Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | $690M | 64.9 | 2.8 | 2.7 | 7.0 | -0.3 | 6 | LEAN BEAR | 0.0 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -5.0 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BEAR | 15.9 |
| APLMW Apollomics, Inc. | $170M | -2.6 | -233.7 | 845.7 | 1188.0 | -75.9 | 3 | LEAN BEAR | -56.5 |
| ARMP Armata Pharmaceuticals, Inc. | $140M | -0.7 | 127.8 | -54.7 | 2953.8 | -35.1 | 2 | LEAN BEAR | -42.4 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 8.9 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| BIOGY BioGaia AB (publ) | $1.3B | 32.0 | 31.8 | 52.6 | 27.5 | 13.1 | 5 | LEAN BEAR | 19.9 |
| OMDA Omada Health | $1.2B | 284.8 | 1.8 | -1.5 | 6.0 | 404.7 | 7 | LEAN BEAR | -26.5 |
| JXFGF Jinxin Fertility Group Limited | $730M | 26.4 | 1.9 | 1.8 | 7.8 | 1.4 | 7 | LEAN BEAR | 3.6 |
| AUNA Auna S.A. | $380M | -17.4 | 0.8 | 4.5 | 2.4 | 9.2 | 7 | LEAN BEAR | -21.1 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| CLVSF CellaVision AB (publ) | $330M | 31.6 | 15.1 | 17.1 | 16.3 | -1.9 | 6 | LEAN BEAR | -27.4 |
| SPHRY Starpharma Holdings Limited | $220M | -26.0 | -46.5 | -441.4 | -725.1 | 186.8 | 4 | LEAN BEAR | 73.3 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | LEAN BEAR | 50.4 |
| ALEC Alector, Inc. | $200M | -1.9 | -385.1 | 66.8 | -692.5 | -82.9 | 1 | LEAN BEAR | 40.0 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 112.0 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.4 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | LEAN BEAR | 46.7 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BEAR | -19.1 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| TRLV Trulieve Cannabis Corp. | $1.8B | — | — | — | — | — | — | BEARISH | — |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| MDRX Veradigm Inc. | $830M | -7.1 | 4.3 | 7.0 | 6.2 | -39.7 | 5 | BEARISH | 0.0 |
| DBVT DBV Technologies S.A. | $230M | -2.6 | -142.6 | -2201.5 | — | -100.0 | 2 | BEARISH | -34.3 |
| RNA Atrium Therapeutics, Inc. | $140M | -2.1 | -36.9 | 455.9 | -672.0 | 235.3 | 5 | BEARISH | -82.9 |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.2 | -13.7 | -105758.3 | — | — | 3 | BEARISH | -11.7 |
| TRDA Entrada Therapeutics, Inc. | $170M | -1.1 | -54.1 | -236.6 | -4762.0 | -94.1 | 1 | BEARISH | -35.4 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.0 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| NEO NeoGenomics, Inc. | $2.2B | -43.6 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | BEARISH | 61.9 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BEARISH | 147.5 |
| SNBIF SanBio Company Limited | $1.3B | -19.5 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| CVSGF CVS Group plc | $1.1B | 52.6 | 5.9 | 7.3 | 2.7 | -22.7 | 6 | BEARISH | 0.7 |
| PKBFF PeakBirch Commerce Inc. | $540M | -0.0 | -16609.0 | 16544.6 | -58.8 | -69.1 | 3 | BEARISH | 0.0 |
| FATE Fate Therapeutics, Inc. | $250M | -2.0 | -60.7 | -140.1 | -1448.6 | -23.4 | 2 | BEARISH | 115.1 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BEARISH | -52.0 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.4 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | BEARISH | -30.7 |
| BPMUF Basilea Pharmaceutica AG | $960M | 16.9 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $710M | 9.0 | 14.3 | 13.4 | 11.4 | 22.0 | 4 | BEARISH | -22.7 |
| BOIRF Boiron S.A. | $550M | 12.7 | 7.2 | 7.8 | 2.0 | 97.0 | 5 | BEARISH | 10.5 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -16.6 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -8.4 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | BEARISH | 82.1 |
| RYHTY Ryman Healthcare Limited | $1.0B | -10.8 | -4.2 | -0.3 | -30.8 | 10.6 | 7 | BEARISH | -23.4 |
| ANGO AngioDynamics, Inc. | $520M | -15.4 | -19.2 | -20.5 | -8.8 | 8.2 | 5 | BEARISH | -0.7 |
| IFRX InflaRx N.V. | $230M | -3.0 | -38.5 | 251.5 | — | -106.2 | 4 | BEARISH | 18.6 |
| ATGGF Actinogen Medical Limited | $140M | -8.5 | -77.5 | -235.8 | — | -100.0 | 1 | BEARISH | 17.2 |
| CLOV Clover Health Investments, Corp. | $2.4B | -114.2 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | BEARISH | 21.2 |
| STLN Starling Oncology, Inc. | $670M | — | — | — | — | — | — | BEARISH | — |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 160.4 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 60.6 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -311.9 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -53.1 |
| CLCGY Clicks Group Limited | $3.1B | 15.8 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | BEARISH | -37.3 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 39.0 |
| LYPHF Luye Pharma Group Ltd. | $1.1B | 7.8 | 4.5 | 6.7 | 13.0 | -2.1 | 6 | BEARISH | 0.8 |
| OCS Oculis Holding AG | $490M | -4.7 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.1 |
| ALXO ALX Oncology Holdings Inc. | $160M | -1.0 | -80.6 | -851.1 | — | — | 4 | BEARISH | -37.1 |
| FBIOP Fortress Biotech, Inc. | $130M | 0.6 | 107.5 | -87.8 | -2.5 | 15.5 | 6 | BEARISH | 131.0 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | BEARISH | — |
| PPTDF PeptiDream Inc. | $870M | -38.0 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 511.6 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BEARISH | -17.2 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 807.7 |
| SMSZF SMS Co., Ltd. | $700M | -14.9 | -40.8 | 31.1 | 18.4 | 6.9 | 6 | BEARISH | 0.0 |
| ZRSEF DocMorris AG | $520M | -10.1 | -30.1 | -29.3 | -8.9 | 11.0 | 2 | BEARISH | 0.0 |
| NPCE NeuroPace, Inc. | $440M | -23.0 | -122.1 | -39.6 | -27.2 | 11.6 | 4 | BEARISH | 24.2 |
| OVID Ovid Therapeutics Inc. | $420M | -4.7 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | BEARISH | 38.6 |
| CTEV Claritev Corporation | $400M | -1.4 | 169.3 | 0.9 | -23.0 | 110.3 | 4 | BEARISH | -67.5 |
| NGNE Neurogene Inc. | $370M | -4.9 | -45.3 | -111469.0 | — | — | 2 | BEARISH | -9.7 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.1 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -28.8 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.6 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 38.8 |
| EXETF Extendicare Inc. | $1.9B | 20.3 | 43.8 | 14.1 | 5.0 | 31.2 | 3 | BEARISH | 74.0 |
| NPRRF Nipro Corporation | $1.4B | — | — | — | — | — | — | BEARISH | 5.8 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 19.6 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -9.1 | -40.0 | 3981.5 | — | — | 4 | BEARISH | 6.2 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.4 | -50.3 | 1635.6 | — | — | 1 | BEARISH | 91.2 |
| CLHLF COLTENE Holding AG | $330M | 19.7 | 16.1 | 12.5 | 3.6 | -2.5 | 5 | BEARISH | -8.4 |
| SMTI Sanara MedTech Inc. | $300M | -8.9 | -147.7 | 19.8 | -1.6 | 12.9 | 5 | BEARISH | 5.7 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | BEARISH | — |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.5 | -35.4 | -415.6 | — | — | 4 | BEARISH | 43.4 |
| GLSI Greenwich LifeSciences, Inc. | $240M | -11.0 | -951.6 | 299.9 | — | — | 2 | BEARISH | 74.4 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BEARISH | -3.2 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -4.1 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BEARISH | -1.1 |
| ALHC Alignment Healthcare, Inc. | $1.7B | 40.0 | 20.0 | -54.4 | 2.7 | 37.2 | 8 | BEARISH | -54.0 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.1 | -47.1 | 961.0 | — | -32.3 | 3 | BEARISH | -10.5 |
| ARVN Arvinas, Inc. | $470M | 39.1 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BEARISH | -19.1 |
| PRTA Prothena Corporation plc | $420M | -10.5 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | BEARISH | -10.3 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.2 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | BEARISH | 31.0 |
| RADLY Raia Drogasil S.A. | $7.2B | 20.7 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -17.4 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 63.0 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 129.1 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BEARISH | -13.8 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| WHTCF WELL Health Technologies Corp. | $770M | 165.0 | 0.5 | 5.4 | -2.7 | 38.6 | 6 | BEARISH | -17.4 |
| FLGT Fulgent Genetics, Inc. | $550M | -7.3 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | BEARISH | -12.8 |
| EOLS Evolus, Inc. | $460M | -14.2 | 138.6 | -20.7 | -9.6 | 13.9 | 5 | BEARISH | 8.5 |
| TTRX Turn Therapeutics Inc. | $310M | -36.1 | -952.4 | 115.0 | — | — | 2 | BEARISH | 105.1 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.3 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BEARISH | -16.9 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| INMD InMode Ltd. | $800M | 10.9 | 12.3 | 44.5 | 17.9 | -6.7 | 5 | BEARISH | -11.3 |
| TKNO Alpha Teknova, Inc. | $340M | -22.4 | -24.2 | -17.2 | -26.0 | 12.3 | 4 | BEARISH | 25.2 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.6 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| VBIZF Viva Biotech Holdings | $400M | 13.1 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| SPRB Spruce Biosciences, Inc. | $130M | -1.1 | -106.0 | 772.2 | — | -100.0 | 4 | BEARISH | -65.7 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 22.2 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -21.2 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -22.5 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -28.7 |
| HROW Harrow Health, Inc. | $1.1B | -29.5 | -114.8 | 1.9 | -24.4 | 21.1 | 5 | BEARISH | -24.5 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.1 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -17.2 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | BEARISH | 15.7 |
| BCYC Bicycle Therapeutics plc | $250M | -1.4 | -32.3 | -1197.0 | -8002.1 | 217.4 | 4 | BEARISH | -52.0 |
| CLVLF Clinuvel Pharmaceuticals Limited | $250M | 10.6 | 13.2 | 126.7 | 41.1 | -1.1 | 6 | BEARISH | -32.0 |
| CDXS Codexis, Inc. | $140M | -3.8 | -69.4 | -37.8 | -80.5 | 35.9 | 3 | BEARISH | -52.6 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 368.6 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 78.7 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 126.7 |
| NHC National HealthCare Corporation | $3.7B | 23.5 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 72.6 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $1.0B | 11.3 | 6.5 | -1.9 | 20.2 | 10.7 | 6 | BEARISH | -2.4 |
| AURA Aura Biosciences, Inc. | $650M | -3.5 | -53.5 | -1360.0 | — | — | 4 | BEARISH | 7.5 |
| IRWD Ironwood Pharmaceuticals, Inc. | $570M | 4.4 | -55.3 | 93.9 | 45.4 | 26.2 | 7 | BEARISH | 111.5 |
| ARCT Arcturus Therapeutics Holdings Inc. | $280M | -3.4 | -46.3 | -2501.0 | -803.8 | -79.1 | 1 | BEARISH | 0.1 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| QTTB Q32 Bio Inc. | $260M | 3.1 | 72.1 | 435.2 | — | — | 5 | BEARISH | 193.3 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -2.2 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 1.3 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| CMOPF Cosmo N.V. | $1.1B | -158.0 | -1.2 | -2.9 | -9.5 | -43.8 | 1 | BEARISH | -22.4 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -10.9 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BEARISH | -28.1 |
| LTGO Latigo Biotherapeutics Inc. | $900M | — | — | — | — | — | — | BEARISH | — |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| MTLZF Metall Zug AG | $680M | -34.8 | -2.8 | -1.4 | -5.6 | -0.3 | 6 | BEARISH | 0.0 |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | BEARISH | -64.9 |
| CAMP CAMP4 Therapeutics Corporation | $210M | -1.6 | -545.9 | 48.4 | -1884.8 | 40.2 | 2 | BEARISH | -1.9 |
| RNAC Cartesian Therapeutics, Inc. | $190M | -1.1 | 241.0 | 37.3 | — | 44.0 | 2 | BEARISH | -29.5 |
| VRXA Veraxa Biotech Holding AG | $140M | — | — | — | — | — | — | BEARISH | — |
| OTLK Outlook Therapeutics, Inc. | $130M | -0.5 | 256.9 | 1372.0 | -225766.7 | -169.4 | 3 | BEARISH | -61.9 |
| IRMD IRadimed Corporation | $1.1B | 46.0 | 23.5 | 50.1 | 25.5 | 11.2 | 6 | BEARISH | 7.8 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -5.6 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | BEARISH | 46.0 |
| ACOG Alpha Cognition Inc | $130M | -8.1 | -55.3 | -198.4 | -144.3 | 232.7 | 2 | BEARISH | 11.1 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| MGTX MeiraGTx Holdings plc | $880M | 12.3 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 7.8 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -1.6 |
| AMGXF AnGes, Inc. | $140M | -3.0 | -160.6 | -111.8 | -531.3 | -16.1 | 4 | BEARISH | 0.0 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.7 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| MNKD MannKind Corporation | $1.0B | -23.4 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | BEARISH | -38.0 |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| SABS SAB Biotherapeutics, Inc. | $260M | 0.9 | -11.3 | -48.4 | — | -100.0 | 3 | BEARISH | 1.3 |
| IMRX Immuneering Corporation | $240M | -3.7 | -52.1 | -112.8 | — | — | 4 | BEARISH | -36.6 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 466.6 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.9 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| BFLY Butterfly Network, Inc. | $1.8B | -25.4 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | BEARISH | 231.8 |
| NVCR Novocure Ltd | $1.7B | -11.2 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 6.3 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -11.2 | -1773.6 | 55.8 | — | -100.0 | 4 | BEARISH | 67.0 |
| OMER Omeros Corporation | $1.2B | 9.1 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.7 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.4 | -845.0 | 24.6 | — | — | 2 | BEARISH | 38.6 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.0 | -214.6 | 174.4 | — | — | 1 | BEARISH | 197.4 |
| MDXG MiMedx Group, Inc. | $570M | 96.6 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -42.3 |
| STTK Shattuck Labs, Inc. | $550M | -11.4 | -39.2 | -29.3 | — | -66.6 | 4 | BEARISH | 200.5 |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 4.6 |
| RZLT Rezolute, Inc. | $370M | -5.4 | -59.0 | 1060.6 | — | — | 2 | BEARISH | -55.3 |
| VRNO Verano Holdings Corp | $370M | -1.4 | -4.5 | 1.5 | -6.0 | — | 3 | BEARISH | — |
| FENC Fennec Pharmaceuticals Inc. | $350M | -81.5 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | BEARISH | 18.1 |
| EBS Emergent BioSolutions Inc. | $320M | -1.9 | -40.3 | -5.5 | -76.9 | -9.6 | 5 | BEARISH | -31.5 |
| DMTRF 3-D Matrix, Ltd. | $310M | 11.9 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
| CUE Cue Biopharma, Inc. | $140M | -0.7 | -1603.5 | 1241.9 | -1943.2 | 354.4 | 3 | BEARISH | -22.2 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.8 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.1 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| SNDA Sonida Senior Living, Inc. | $1.6B | -5.3 | -25.2 | -2.9 | -11.8 | 49.4 | 4 | BEARISH | 23.9 |
| ETON Eton Pharmaceuticals, Inc. | $1.4B | 109.0 | 36.0 | 33.3 | 30.8 | 81.5 | 7 | BEARISH | 177.1 |
| MEDOF Medios AG | $1.3B | 23.5 | 2.1 | 2.8 | 0.6 | 10.0 | 6 | BEARISH | 0.0 |
| GHRS GH Research PLC | $1.2B | -20.0 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 43.5 |
| CSBTF Kuros Biosciences AG | $950M | 109.9 | 9.6 | 9.2 | 4.8 | 29.1 | 4 | BEARISH | -39.6 |
| IART Integra LifeSciences Holdings Corporation | $930M | 70.5 | 1.2 | 13.4 | 3.6 | 0.8 | 6 | BEARISH | -25.6 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.3 | -49.2 | -201.4 | — | — | 3 | BEARISH | 110.7 |
| AKTS Aktis Oncology, Inc. | $850M | -15.8 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 373763.6 |
| DSGN Design Therapeutics, Inc. | $640M | -9.1 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 85.5 |
| SLDB Solid Biosciences Inc. | $630M | -3.2 | -65.5 | -1012.6 | — | — | 3 | BEARISH | 10.1 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.8 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 24.4 |
| ANL Adlai Nortye Ltd. | $560M | -5.5 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 549.1 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.7 | -19.5 | 523.8 | — | — | 2 | BEARISH | -11.9 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 29.9 |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -21.1 |
| WHWK Whitehawk Therapeutics Inc | $180M | -3.0 | -45.0 | 963.4 | — | -100.0 | 1 | BEARISH | 38.2 |
| ANTX AN2 Therapeutics, Inc. | $130M | -3.5 | -50.1 | 1243.3 | — | — | 2 | BEARISH | 229.9 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| HBMHF HBM Holdings Limited | $1.3B | 12.5 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| RAFLF Raffles Medical Group Ltd | $1.2B | 22.0 | 5.8 | 7.3 | 8.2 | -2.8 | 7 | BEARISH | -20.0 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -5.6 | -41.0 | 583.9 | — | — | 2 | BEARISH | 2.0 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -36.8 |
| EBOSY EBOS Group Limited | $1.0B | 15.3 | 5.0 | 4.4 | 1.7 | -8.1 | 6 | BEARISH | -47.5 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.8 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -4.3 |
| ALMS Alumis Inc. | $880M | -1.8 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | BEARISH | 47.2 |
| XVIPY Xvivo Perfusion AB (publ) | $690M | 49.4 | 5.9 | 4.6 | 17.7 | 17.5 | 6 | BEARISH | — |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| SWDCF Swedencare AB (publ) | $370M | 35.2 | 1.2 | 1.7 | 3.9 | 1.4 | 7 | BEARISH | -46.5 |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.5 | -55.7 | 460.5 | — | — | 3 | BEARISH | 52.9 |
| BNTC Benitec Biopharma Inc. | $300M | -8.9 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -35.5 |
| IPSC Century Therapeutics, Inc. | $260M | -1.4 | -49.7 | -60.0 | — | -100.0 | 2 | BEARISH | 151.2 |
| RCKT Rocket Pharmaceuticals, Inc. | $250M | -15.5 | -4.8 | -137.8 | — | — | 3 | BEARISH | -36.4 |
| BOVNF BioInvent International AB (publ) | $220M | -2.8 | -88.2 | 20101.5 | -964.0 | -87.2 | 1 | BEARISH | 0.0 |
| CHRS Coherus Oncology, Inc. | $160M | -1.0 | -145.4 | 1854.0 | -144.2 | -64.3 | 2 | BEARISH | -35.1 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 168.0 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 20.8 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.7 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -42.7 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| WGS GeneDx Holdings Corp. | $1.7B | -17.2 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -51.3 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -31.3 |
| KURA Kura Oncology, Inc. | $850M | -2.9 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BEARISH | 2.1 |
| HELP Helus Pharma Inc. | $630M | -2.6 | -56.3 | -143.0 | — | — | 2 | BEARISH | — |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.3 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | BEARISH | 5.5 |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.5 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -5.2 |
| DCTH Delcath Systems, Inc. | $500M | 1344.2 | 0.5 | -2.7 | 9.2 | 35.8 | 6 | BEARISH | 44.2 |
| AQST Aquestive Therapeutics, Inc. | $500M | -6.2 | 121.1 | 43.4 | -165.5 | 22.6 | 5 | BEARISH | -40.5 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -6.9 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 29.4 |
| IRD Opus Genetics, Inc. | $290M | -2.7 | -4796.5 | 59.8 | -1072.6 | -36.1 | 3 | BEARISH | 73.9 |
| AGEN Agenus Inc. | $290M | 2.4 | -33.2 | -20.4 | -1.6 | 30.5 | 6 | BEARISH | 60.6 |
| GALT Galectin Therapeutics Inc. | $210M | -8.0 | 21.9 | 99.4 | — | — | 2 | BEARISH | -35.4 |
| CGEN Compugen Ltd. | $180M | 5.2 | 49.6 | -90.2 | -269.3 | 886.7 | 5 | BEARISH | 9.4 |
| MGNX MacroGenics, Inc. | $140M | -10.8 | -32.6 | 33.8 | 59.4 | 2.3 | 2 | BEARISH | 32.6 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.3 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.6 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| ARSUF Fagron N.V. | $2.0B | 18.9 | 16.7 | 10.8 | 8.4 | 11.8 | 4 | BEARISH | 9.8 |
| CURLF Curaleaf Holdings, Inc. | $1.8B | -62.5 | -4.2 | 0.5 | 3.7 | 2.7 | 7 | BEARISH | -2.1 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| ELEAF EL.En. S.p.A. | $1.4B | 13.7 | 13.2 | 29.1 | 6.0 | 25.8 | 8 | BEARISH | 37.9 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 219.4 |
| MDCLF MedinCell S.A. | $1.1B | -29.2 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| IMMX Immix Biopharma, Inc. | $680M | -9.3 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 123.0 |
| CADL Candel Therapeutics, Inc. | $610M | -5.9 | -81.8 | 219.4 | — | — | 2 | BEARISH | 52.8 |
| CLYM Climb Bio, Inc. | $590M | -11.6 | -27.1 | -88.6 | — | — | 2 | BEARISH | 380.9 |
| AVR Anteris Technologies Global Corp. | $570M | -2.2 | -75.1 | 3136.2 | -2884.3 | 31.1 | 5 | BEARISH | 20.0 |
| GNFTF Genfit S.A. | $470M | -5.2 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| AVCTF Avacta Group Plc | $420M | -6.7 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| SENS Senseonics Holdings, Inc. | $400M | -3.7 | -118.2 | -901.4 | -253.4 | 79.0 | 3 | BEARISH | 18.8 |
| VREOF Vireo Growth Inc. | $310M | -4.1 | -4.6 | -0.7 | -0.0 | — | 3 | BEARISH | — |
| IKT Inhibikase Therapeutics, Inc. | $220M | -3.3 | -52.0 | 920.5 | — | — | 3 | BEARISH | 1.9 |
| PLX Protalix BioTherapeutics, Inc. | $210M | 10.5 | 31.2 | 47.1 | 19.0 | 30.1 | 5 | BEARISH | 7.2 |
| PRQR ProQR Therapeutics N.V. | $180M | -3.0 | -57.9 | 139.7 | -99.6 | 12.7 | 2 | BEARISH | -54.0 |
| ORMP Oramed Pharmaceuticals Inc. | $170M | 1.0 | 74.1 | -4.3 | — | -100.0 | 4 | BEARISH | 74.1 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.1 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 42.8 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.0 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 7.7 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| ADDLF AddLife AB (publ) | $1.9B | 34.5 | 11.3 | 7.0 | 4.9 | 1.1 | 4 | BEARISH | -62.5 |
| VIMGF Vimian Group AB (publ) | $1.5B | 48.7 | 5.4 | 6.4 | 7.4 | 8.9 | 7 | BEARISH | -8.0 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.4 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 1.2 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $1.1B | 18.6 | 5.7 | 8.4 | 19.4 | 24.4 | 6 | BEARISH | 20.0 |
| TTALF Terveystalo Oyj | $910M | 13.3 | 10.3 | 6.3 | 2.1 | -8.7 | 4 | BEARISH | -44.5 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $820M | -4.8 | -4.9 | 0.0 | -14.3 | 5.6 | 6 | BEARISH | -40.3 |
| ARDX Ardelyx, Inc. | $770M | -13.2 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -40.5 |
| GERN Geron Corporation | $720M | -11.5 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -7.3 |
| SANA Sana Biotechnology, Inc. | $700M | -3.2 | -152.9 | -242.3 | — | — | 3 | BEARISH | -55.8 |
| TGRNF Tong Ren Tang Technologies Co. Ltd. | $660M | 10.8 | 4.1 | 12.2 | 8.2 | -18.2 | 6 | BEARISH | -43.0 |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| WVE Wave Life Sciences Ltd. | $630M | -3.2 | -80.0 | -1243.7 | -470.5 | -35.1 | 4 | BEARISH | -51.6 |
| CRWRF Craneware plc | $620M | 25.9 | 6.0 | 6.8 | 9.7 | 4.2 | 7 | BEARISH | -43.9 |
| GYRE Gyre Therapeutics, Inc. | $620M | -32.8 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | BEARISH | -20.1 |
| ANNX Annexon, Inc. | $610M | -3.2 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 17.1 |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.3 | -52.7 | 585.3 | — | — | 2 | BEARISH | -12.3 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.2 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.1 |
| KSRBF Kossan Rubber Industries Bhd | $480M | 16.9 | 5.0 | 8.5 | 11.3 | 1.0 | 5 | BEARISH | -43.2 |
| BWAY BrainsWay Ltd. | $440M | 47.1 | 13.0 | 31.1 | 15.8 | 32.3 | 5 | BEARISH | 38.3 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.7 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -59.1 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.6 | -57.5 | -366.6 | — | — | 2 | BEARISH | — |
| TLRY Tilray Brands, Inc. | $310M | -2.0 | -8.8 | -3.4 | -16.8 | -16.9 | 3 | BEARISH | -81.4 |
| SPHDF Santhera Pharmaceuticals Holding AG | $280M | -6.6 | 729.6 | 111.3 | -44.5 | 106.3 | 7 | BEARISH | 49.1 |
| VOGX Vogenx Inc. | $260M | — | — | — | — | — | — | BEARISH | — |
| ORYZF Oryzon Genomics S.A. | $250M | -80.4 | -3.0 | -7.2 | -1.6 | 12.6 | 4 | BEARISH | -14.1 |
| LRMR Larimar Therapeutics, Inc. | $240M | -1.2 | -139.6 | 590.9 | — | — | 2 | BEARISH | -43.2 |
| HLOSF Healios K.K. | $240M | 56.3 | 3.7 | -129.2 | 17028.6 | -47.1 | 4 | BEARISH | -48.6 |
| VNDA Vanda Pharmaceuticals Inc. | $240M | -0.9 | -77.8 | -201.0 | -123.7 | 6.0 | 3 | BEARISH | -27.4 |
| LXEO Lexeo Therapeutics, Inc. Common Stock | $230M | -2.5 | -46.8 | -249.1 | — | — | 3 | BEARISH | -68.9 |
| IPHYF Innate Pharma S.A. | $210M | -2.5 | 267.9 | 119.2 | -343.8 | 32.0 | 3 | BEARISH | -24.5 |
| BBOT BridgeBio Oncology Therapeutics Inc. | $210M | -0.0 | -56.4 | -157.3 | — | — | 1 | BEARISH | -75.5 |
| EVMN Evommune, Inc. | $190M | -1.5 | -29.6 | -82.4 | — | — | 2 | BEARISH | — |
| BIOA BioAge Labs Inc. | $190M | -2.3 | -28.2 | -142.3 | -1064.7 | 168.1 | 4 | BEARISH | -28.0 |
| ELDN Eledon Pharmaceuticals, Inc. | $190M | -2.4 | -110.7 | 411.1 | — | — | 2 | BEARISH | -30.8 |
| AKBA Akebia Therapeutics, Inc. | $160M | -6.1 | -109.4 | 15.6 | -18.1 | 7.5 | 6 | BEARISH | -78.2 |
| ZNTL Zentalis Pharmaceuticals, Inc. | $160M | -0.8 | -83.7 | -2245.4 | — | -100.0 | 2 | BEARISH | 15.8 |
| NBP NovaBridge Biosciences | $160M | -2.2 | -45.7 | -617.8 | — | — | 1 | BEARISH | -70.4 |
| NGEN NervGen Pharma Corp. Common stock | $150M | — | — | — | — | — | — | BEARISH | — |
| MDWD MediWound Ltd. | $150M | -7.7 | -72.4 | -255.1 | -239.1 | -40.3 | 2 | BEARISH | -31.9 |
| TARA Protara Therapeutics, Inc. | $140M | -1.8 | -45.8 | -41.3 | — | — | 2 | BEARISH | -51.6 |
| NKTX Nkarta, Inc. | $130M | -1.1 | -38.8 | -75.4 | — | — | 1 | BEARISH | -15.0 |
| MENS Jyong Biotech Ltd. Ordinary Shares | $130M | — | — | — | — | — | — | BEARISH | -96.9 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.8 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -46.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| ULIHF The United Laboratories International Holdings Limited | $1.9B | 20.5 | 3.3 | 4.4 | 5.6 | -16.6 | 4 | BEARISH | -49.9 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| FDMDF 4DMedical Limited | $1.6B | -9.2 | -174.5 | 43.4 | -1194.8 | 20.5 | 3 | BEARISH | 94.2 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| GTBIF Green Thumb Industries Inc. | $1.4B | 11.8 | 7.0 | 2.5 | 1.6 | 4.8 | 7 | BEARISH | -16.3 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.1 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -18.3 |
| MCRPF MicroPort Scientific Corp. | $1.1B | 31.2 | 6.1 | -1.7 | 21.3 | -3.5 | 5 | BEARISH | -63.2 |
| LFTSF LifeTech Scientific Corporation | $1.0B | 103.0 | 7.3 | 6.9 | -5.7 | 103.7 | 4 | BEARISH | -14.3 |
| SVRA Savara Inc. | $870M | -8.4 | -105.5 | -15438.9 | — | — | 2 | BEARISH | 11.5 |
| IVEVF Inventiva S.A. | $750M | -6.2 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| ATTO Attovia Therapeutics, Inc. | $630M | -15.3 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 272.2 |
| NNCSF Nanosonics Limited | $620M | 53.0 | 8.3 | 15.6 | 8.1 | 2.4 | 4 | BEARISH | -39.9 |
| EVOTF Evotec SE | $590M | -2.6 | -26.1 | -14.9 | -32.5 | -7.7 | 2 | BEARISH | -54.3 |
| PROK ProKidney Corp. | $470M | -2.7 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.5 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.7 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -55.7 |
| SSII SS Innovations International, Inc. | $450M | -39.0 | -26.1 | -15.6 | -19.1 | 108.5 | 3 | BEARISH | -72.1 |
| RGNX REGENXBIO Inc. | $440M | -1.7 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -49.4 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| CALZF PolyNovo Limited | $430M | 82.1 | 8.4 | 9.3 | 10.0 | 12.8 | 7 | BEARISH | -38.6 |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.9 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 2.5 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -46.0 |
| ASMB Assembly Biosciences, Inc. | $400M | 37.0 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -30.6 |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 18.6 |
| NIKA Nika Pharmaceuticals Inc. | $370M | -4711.6 | 26.8 | 18.5 | — | 100.0 | 3 | BEARISH | 8.5 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -61.6 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | -1.6 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -1.9 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.3 |
| FULC Fulcrum Therapeutics, Inc. | $280M | -3.1 | -32.4 | 2389.1 | — | — | 4 | BEARISH | -59.9 |
| CTNM Contineum Therapeutics, Inc. | $270M | -5.2 | -28.0 | -541.6 | — | — | 4 | BEARISH | -18.6 |
| ABEO Abeona Therapeutics Inc. | $250M | -3.9 | -43.1 | -5983.3 | -177.4 | 6280.0 | 2 | BEARISH | -18.8 |
| CABA Cabaletta Bio, Inc. | $250M | -0.9 | -93.2 | -1308.0 | — | — | 3 | BEARISH | -40.9 |
| SCTX Scribe Therapeutics Inc. | $250M | — | — | — | — | — | — | BEARISH | — |
| OCGN Ocugen, Inc. | $250M | -2.9 | 1211.7 | 190.2 | -1671.8 | -3.7 | 2 | BEARISH | -52.4 |
| ACIU AC Immune S.A. | $250M | -4.2 | -78.5 | 96.7 | 12.4 | -39.5 | 2 | BEARISH | -30.8 |
| PALI Palisade Bio, Inc. | $230M | -2.3 | -51.4 | 815.6 | -2114.8 | — | 5 | BEARISH | -31.0 |
| NAGE Niagen Bioscience Inc | $190M | 12.9 | 21.8 | 44.7 | 3.2 | 11.0 | 6 | BEARISH | -67.0 |
| IVVD Invivyd, Inc. | $180M | -1.5 | -95.9 | -302.5 | -310.8 | 26.3 | 2 | BEARISH | -73.2 |
| SION Sionna Therapeutics, Inc. | $160M | -1.8 | -32.3 | -137.7 | — | — | 0 | BEARISH | -90.1 |
| CNTN Canton Strategic Holdings Inc | $150M | -1.2 | -14.6 | -7.2 | -1287.2 | — | 2 | BEARISH | — |
| UPB Upstream Bio, Inc. | $150M | -1.0 | -46.0 | -1266.4 | -5136.1 | 49.2 | 3 | BEARISH | -83.0 |
| STRO Sutro Biopharma, Inc. | $150M | -0.5 | 266.8 | 43.6 | -391.6 | -56.3 | 4 | BEARISH | -15.5 |
| CMPX Compass Therapeutics, Inc. | $140M | -1.8 | -56.7 | 1526.3 | — | — | 4 | BEARISH | -81.2 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
EDIT vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F